CLINICAL STUDY PROTOCOL
Study Title: A Phase 1b/2a S tudy in Participants with EarlyStage COVID -19 to 
Evaluate the Safet y, Efficacy ,and Pharmacokinetics of Remdesivir
Administered by  Inhalation
Sponsor: Gilead Sciences, Inc.
333 L akeside Drive
Foster City , CA 94404
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:150732
Not Applicable
[STUDY_ID_REMOVED]
Indication: COVID -19
Protocol ID: GS-US-553-9020
Contact Information: The medical monitor name and contact information will be 
provided on the Key  Study  Team Contact List.
Protocol 
Version/Date:Original: 31July 2020
Amendment 1
: 26 August 2020
Amendment 2: 14December 2020
Amendment 3: 13January  2021
This study  will be conducted under US Food & Drug Administration investigational new drug 
(IND)regulations (21 C ode of Federal Regulations Part 312); however, sites located in the 
European Economic Area and Switzerland are not included under the IND and are considered 
non-IND sites.
CONFIDENTIALITY STAT EMENT
The information contained in this document, particularly unpublished data, is the propert y or 
under control of Gilead Sciences, Inc., and is provided to you in confid ence as an investigator, 
potential investigator, or consultant, for review b y you, your staff, and an applicable 
Institutional Review Board or Independent Ethics Committee. The information is only  to be 
used by  you in connection with authorized clinical st udies of the investigational drug 
described in the protocol. You will not disclose any of the information to others without 
written authorization from Gilead Sciences, Inc., except to the extent necessary  to obtain 
informed consent from those persons to wh om the drug may  be administered.
(rJ GILEAiJ 
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-553-9020 
Gilead Sciences, Inc. FINAL 
Amendment3 
TABLE OF CONTENTS 
TABL E O F CONTE NTS .............................................................................................................................................. 2 
PROTO COL SYN OPSIS .............................................................................................................................................. 5 
GLOSSARY O F ABBREVIATIO NS AND D EFINITIO N OF TE RMS .................................................................... 13 
I. INTRO DUCT ION .............................................................................................................................................. 16 
1.1. Backgroun d ............................................................................................................................................ 16 
1.2. Remd esivir (ROY; GS-5734) for Inhaled Adm inistration ..................................................................... 16 
1.2.1. General Information ............................................................................................................. 16 
1.2.2. Addi tional Clinical Studies of Remd esivir ........................................................................... 17 
1.2.3. Rationale for This S tudy ....................................................................................................... 18 
1.3. Rat ional e for the Do se Selection ............................................................................................................ 19 
1.4. Risk/Bene fit Assess ment for the Study .................................................................................................. 20 
1.5. Com plianc e ............................................................................................................................................ 2 1 
2. OBJECTIYES ..................................................................................................................................................... 22 
3. STUDY D ESIGN ................................................................................................................................................ 23 
3.1. 
3.2. 
3.3. 
3.4. 
3.5. 3.6. 
3.7. 
3.8. 
3.9. Endpoints ............................................................................................................................................... 23 
Study Design .......................................................................................................................................... 24 
Study Trea
tments ................................................................................................................................... 24 
Safety Review Team .............................................................................................................................. 26 
Duration ofTreatment ............................................................................................................................ 27 
Discontinuation Criteria ......................................................................................................................... 27 
End of Study ........................................................................................................................................... 27 
Posts tudy Care ........................................................................................................................................ 27 
Source Data ............................................................................................................................................ 28 
4. SUBJECT PO PU LAT ION .................................................................................................................................. 29 
4.1. Nu mber of Subj ects and Subj ect Selection ............................................................................................ 29 
4.1.1. Subj ect Replacement ............................................................................................................ 29 
4.2. Inclu sion Criteria .................................................................................................................................... 29 
4.3. Exclusion Criteria ................................................................................................................................... 29 
5. INYES TIGATIONAL MEDICINAL PRODUCTS ........................................................................................... 3 1 
5.1. Rando mization, Blindin g, and Treatment C odes Access ....................................................................... 3 1 
5.1.1. Rando mizat ion ..................................................................................................................... 3 1 
5.1.2. Blindin g ................................................................................................................................ 3 1 
5.1.3. P rocedures for Bre aking Tre atment C odes ........................................................................... 32 
5.2. D escription and Handlin g of Remd esivir ............................................................................................... 32 
5.2.1. Formulation .......................................................................................................................... 32 
5.2.2. Pac kaging and Labeling ....................................................................................................... 33 
5.2.3. St orage and Handlin g ........................................................................................................... 33 
5.3. Dosa ge and Administration of Remd esivir ............................................................................................ 34 
5.4. Di spensing, Accountability, and Disposal or Re turn of Study Trea tment .............................................. 34 
5.5. Prior and C oncomit ant Me dication s ....................................................................................................... 35 
6. STUDY PROCEDURES .................................................................................................................................... 36 
6.1. Subj ect Enroll ment and Trea tment A ssignment ..................................................................................... 36 
6.2. Pretreatment A ssess ments ...................................................................................................................... 36 
CONFIDENTI AL Page 2 13 January 2021 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 3 13January 20216.2.1. Study Parts A, B, and C: Screening Visit ............................................................................. 36
6.2.2. Study Parts A and B: Baseline/Day 1 Assessments .............................................................. 37
6.3. Study Parts A and B: Daily Study Assessments (Days 2 -5)................................................................... 38
6.4. Study Parts A and B: Follow -Up Assessments (Days 7 and 14) ............................................................ 39
6.5. Study Parts A and B: Day 28 Follo w-Up Assessment (± 5 days) .......................................................... 40
6.6. Study Part C: Baseline/Day 1, Days 3, 5, and 7 Assessments ................................................................ 40
6.7. Study Part C: Days 2 and 4 Assessments ............................................................................................... 41
6.8. Study Part C: Follow -Up Assessments (Days 14 and 28) ...................................................................... 41
6.9. Chest X -Ray........................................................................................................................................... 42
6.10. FEV 1....................................................................................................................................................... 42
6.11. Clinical Laboratory Assessments ........................................................................................................... 42
6.12. Pharm acokinetic Assessments ................................................................................................................ 43
6.13. Assessments for Early Discontinuation from Study ............................................................................... 43
6.13.1. Criteria for Discontinuation of Study Treatment .................................................................. 43
6.14. End of Study ........................................................................................................................................... 44
6.15. Poststudy Care ........................................................................................................................................ 44
6.16. Sample Storage ....................................................................................................................................... 44
7. ADVERSE E VENTS AND TOXICITY M ANAGEMENT ............................................................................... 45
7.1. Definitions of Adverse Events and Serious Adverse Events .................................................................. 45
7.1.1. Adverse Events ..................................................................................................................... 45
7.1.2. Serious Adverse Events ........................................................................................................ 45
7.1.3. Study Treatments and Gilead Concomitant Therapy Special Situations 
Reports ................................................................................................................................. 46
7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................. 47
7.2.1. Assessment of Causality for Study Treatments and Procedures ........................................... 47
7.2.2. Assessment of Severity ........................................................................................................ 47
7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events ....................................................................................................................................... 48
7.3.1. Requirements for Collection Prior to Study Treatment Initiation ........................................ 48
7.3.2. Adverse Events ..................................................................................................................... 48
7.3.3. Serious Adverse Events ........................................................................................................ 48
7.3.4. Study Treatment Special Situations Reports ........................................................................ 48
7.3.5. Concomitant Therapy Reports .............................................................................................. 49
7.4. Reporting Process for Serious Adverse Events and Special Situation Reports ...................................... 49
7.4.1. Serious Adverse Event Reporting Process ........................................................................... 49
7.4.2. Special Situations Reporting Process ................................................................................... 50
7.5. Gilead Reporting Requirements ............................................................................................................. 51
7.6. Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or 
Serious Adverse Events .......................................................................................................................... 52
7.7. Toxicity Management ............................................................................................................................ 52
8. STATISTICAL CONSIDER ATIONS ................................................................................................................ 54
8.1. Analysis Objectives and Endpoints ........................................................................................................ 54
8.1.1. Analysis Objectives .............................................................................................................. 54
8.1.2. Primary Endpoint ................................................................................................................. 54
8.1.3. Secondary Endpoint ............................................................................................................. 54
8.2. Planned Analyses ................................................................................................................................... 55
8.2.1. Interim Analysis ................................................................................................................... 55
8.2.2. Final Analysis ....................................................................................................................... 56
8.3. Analysis Conventions ............................................................................................................................. 56
8.3.1. Analysis Sets ........................................................................................................................ 56
8.3.2. Data Handling Conventions ................................................................................................. 56
CCI-
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 4 13January 20218.4. Dem ographic and Baseline Characteristics Analysis ............................................................................. 57
8.5. Efficacy Analysis ................................................................................................................................... 57
8.5.1. Primary Analysis .................................................................................................................. 57
8.5.2. Secondary Analyses ............................................................................................................. 57
8.6. Safety Analysis ....................................................................................................................................... 57
8.6.1. Extent of Exposure ............................................................................................................... 57
8.6.2. Adverse Events ..................................................................................................................... 57
8.6.3. Laboratory Evaluations ........................................................................................................ 58
8.7. Adjustments for Multiplicity .................................................................................................................. 58
8.8. Pharm acokinetic Analysis ...................................................................................................................... 58
8.9. Sample Size ............................................................................................................................................ 58
9. RESPONSIBILITIES .......................................................................................................................................... 59
9.1. Investigator Responsibilities .................................................................................................................. 59
9.1.1. Good Clinical Practice .......................................................................................................... 59
9.1.2. Financial Disclosure ............................................................................................................. 59
9.1.3. Institutional Review Board/Independent Ethics Committee Revie w and 
Approval ............................................................................................................................... 59
9.1.4. Informed Consent ................................................................
................................................. 59
9.1.5. Confidentiality ...................................................................................................................... 60
9.1.6. Study Files and Retention of Records .................................................................................. 60
9.1.7. Case Report Forms ............................................................................................................... 62
9.1.8. Investigator Inspections ........................................................................................................ 62
9.1.9. Protocol Compliance ............................................................................................................ 62
9.2. Sponsor Responsibilities ........................................................................................................................ 62
9.2.1. Protocol Modifications ......................................................................................................... 62
9.2.2. Study Report and Publications ............................................................................................. 63
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 63
9.3.1. Payment Reporting ............................................................................................................... 63
9.3.2. Access to Information for Monitoring .................................................................................. 63
9.3.3. Access to Information for Auditing or Inspections .............................................................. 64
9.3.4. Study Discontinuation .......................................................................................................... 64
10. REFERENCES ................................................................................................................................................... 65
11. APPENDICES .................................................................................................................................................... 66
Appendix 1. Investigator Signature Page .................................................................................................... 67
Appendix 2. Pandemic Risk Assessment and Mitigation Plan .................................................................... 68
Appendix 3. Study Procedures Tables ........................................................................................................ 71
Appendix 4. Management of Clinical and Laboratory Adverse Events ...................................................... 75
Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................... 76
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-553-9020 
Gilead Sciences, Inc. 
Study Title: 
IND Number: 
EudraCT Number: 
Clinical Trials.gov 
Identifier: 
Study Centers 
Planned: 
Objectives: 
CONFIDENT IAL PROTOCOL SYNOPSIS 
Gilead Sciences, Inc. 
333 Lakeside Drive 
Foster City, CA 94404 FINAL 
Amendment3 
A Phase 1b/2a Study in Participan ts with Early Stage COVID-19 to 
Evaluate the Safety, Efficacy, and Phannacokin etics of Remdesivir 
Admini stered by Inhalation 
150732 
Not Applicable 
[STUDY_ID_REMOVED] 
Up to approx imately 50 centers globally 
The primary object ive of this study is: 
• To character ize the impact of inhaled remdes ivir (RDV) on severe 
acute respiratory syndro me (SA RS)-coronav irus (CoV)-2 viral 
load in participants with early stage corona virus disease 2019 
(COVID-19) 
The secondary object ives of this study are: 
• To evaluate the safety and tolerability of inhaled Remdesivir for 
Injection fonnu lation in participants with early stage COVID-19 
• To evaluate the phannacokinetics (PK) of inhaled Remdesivir for 
Injection fonnu lation and its metabo lites in partic ipants with early 
stage COVID-19 in Parts A and B 
• To character ize and evaluate disease progression from base line 
• To character ize the efficac y, safety, and tolerability of Remdesivir 
for Inhalation Solution fonnu lation administered with a 
mouthpi ece in Part C of the study 
Page 5 13 January 2021 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 6 13January 2021Study Design: This is a Phase 1b/2a randomized, blind ed, placebo -controlled, 
multicenter study  of RDV therapy  for outpatients with earl y stage 
COVID -19 evaluating inhal edRDV (treatment arm) or 
placebo- to-match (PTM) (placebo arm).
The study  will feature multiple parts : Part A , Part B ,and Part C .
The goal of the stud y is to evaluate the safet y, efficacy , and PK of 
inhaled RDV in participants with early stage COVID -
19. Parts A and 
B of the stud y will evaluate 2 different nominal dosing regimens 
(31mg in Part A and 62 mg in Part B [Remdesivir for Injection 
formulation] ) for up to 5 days of dail y dosing. Safety  and efficacy  of 
an inhaled RDV formulation with reduced sulfobuty lether 
β
-cyclodextrin sodium (SBECD )content ( Remdesivir for Inhalation 
Solution formulation ) will be evaluated in Part C of the study .The 
RDV formulation used within each Study  Part is as follows:
Study 
Part Form ulationVolume/Nominal 
Dose (m g)Duration of 
Nebulization 
(minutes)
Part A Remdesivir for Injection 
formulation via nebulization31 mga17 minutes
Part B Remdesivir for Injection 
formulation via nebulization62 mga34 minutes
Part C Remdesivir for Inhalation 
Solution formulation via 
nebulization39mgb19 minutes 
a Sealed Facemask: Nominal dose of 31 mgand 62 mg to achieve a deposited dose of 5 mg
and 10 mg, respectively : Overall delivery efficiency  1 6.1%.
b Mouthpiece: Nominal dose of 3 9mg to achieve a deposited dose of 10 mg: Overall 
delivery efficiency  2 5.6%.
The term “inhaled remdesivir ”refers to both the Remdesivir for 
Injection formulation and Remdesivir for Inhalation Solution
formulation when administered via nebulization using the LC Sprint. 
Part A: In Part A, approximately  36 participants who meet all 
eligibility  criteria will be randomized in a 1:1:1 ratio into one of the 
following 3 treatment groups:
Treatment Group 1: 31 mg inhaled Remdesivir for Injection 
formulation daily  for 5 day s
Treatment Group 2: 31 mg inhaled Remdesi vir for Injection 
formulation daily  for 3 days followed by  PTM daily  for 2 day s
Treatment Group 3: PTM daily  for 5 day s
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 7 13January 2021Part B: In Part B, if supported by  evaluation in healthy  volunteers in 
the Phase 1a study , an additional 36 total participants may  be 
randomized in a 1:1:1 ratio into one of the following 3treatment 
groups:
Treatment Group 4: 62 mg inhaled Remdesivir for Injection 
formulation daily  for up to 5 day s
Treatment Group 5: 62 mg inhaled Remdesivir for Injection 
formulation daily  for up to 3 day s followed by  PTM daily  through 
Day 5
Treatment Group 6: PTM daily  for 5 day s
Part C: Part C of the study  will include an expanded safet y and 
efficacy  assessment of an additional 80 participants. Participants in 
Part C will be enrolled after review of preliminary safet y data from 
PartsA and B through at least Day  7. A pproximately  80 participants 
will be randomized in a 
3:1ratio into one of the following 2 treatment 
groups: 
Treatment Group 7:39 mg Remdesivir for Inhalation So lution 
formulation once daily for 5 days by mouthpiece
Treatment Group 8:PTM daily  for 5 day sby mouthpiece
Number of 
Participants 
Planned:Part A and Part B: Approximately  36 participants will be enrolled in 
each part .
Part C: Approximately  80 participa nts will be enrolled .
Target Population: Parts A and B: Participants ≥18 years of age with polymerase chain 
reaction ( PCR)- confirmed early stage COVID -19
Part C: Participants ≥ 18 years of age with early stage COVID -19
confirmed by  nucleic acid testing ordirect antigen testing
Duration of 
Treatment:RDV and/or PTM will be administered for 5 day s.
Diagnosis and 
Main Eligibility  
Criteria:Eligible participants will be at least 18 years of age who meet the 
following eligibility  criteria:
Key Inclusion Criteria:
Willing and able to provide written informed consent, or with a 
legal representative who can provide informed consent
Severe acute respiratory  syndrome coronavirus 2 ( SARS -CoV-2)
infection first confirmed by  PCR (Parts A and B) or by nucleic 
acid testing or direct antigen testing (Part C) with sample collected 
≤ 4days prior to randomization
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 8 13January 2021COVID -19 s ymptom onset ≤ 7 day s prior to randomization
Oxygen saturation as measured b y pulse oximetry ( SpO2) >94% 
on room air
Key Exclusion Criteria:
Ongoing or prior p articipation in any  other clinical trial of an 
experimental vaccine or treatment for COVID -19
Prior or current hospitalization for COVID - 19or need for 
hospitalization
Treatment of COVID -19 with other agents with actual or possible 
direct antiviral activity  against SARS -CoV -2including IV RDV or 
administration of any  SARS -CoV -2 (or COVID -19) vaccine
Patients chronicall y administered chloroquine or 
hydroxychloroquine for any  reason are to be excluded
Requiring 
oxygen supplementation
Positive pregnancy  test
Breastfeeding female
Known hy persensitivity  to the study  treatment , its metabolites, or 
formulation excipient
Pre-existing pulmonary  conditions such as 
chronic obstructive 
pulmonary  disease or asthma ( Parts Aand B only)
Study  Procedures/
Frequency :At screening, after the participant has provided informed consent, 
assessments will include but are not limited to the following: 
demographic and baseline characteristics, medical history , and 
concomitant medications will be documented. Body  weight and height 
will be measured. A urine pregnancy  test will be performed for women 
of childbearing potential. Vital signs including heart ra te, temperature, 
blood pressure, and SpO 2will be recorded. A complete phy sical 
examination will be performed.
Study Parts A and B:
On Day s 1 through 5, assessments will include a sy mptom - directed 
physical examination. A 12-lead electrocardiogram ( ECG ) will be 
performed at Day  1. Vital signs will be measured predose and 
postdose . Concomitant medications and adverse events (AEs) will be 
documented. Laboratory  samples will be obtained for safety  
assessment s(Day s 1, 3, 5) andPK assessments (Day s 1, 3, 5) .
Nasophary ngeal , orophary ngeal swab samples and saliva samples for 
SARS -CoV -
2 testing and possible viral resistance testing will be 
performed on Day s 1through 5. A chest x -ray will be performed at
Day 1 to identify  any pulmonary  infiltrates. Forced expira tory volume 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 9 13January 2021in the first second of expiration (FEV 1) will be performed dail y during 
treatment day s and will be performed both predose and 10 minutes 
postdose. Repeat FEV 1should be performed at 30 minutes postdose if 
there is > 15% reduction in FEV 1at 10 minutes postdose compared 
with the same day  predose FEV 1.FEV 1assessment may  also be 
performed if there is a clinical concern of bronchospasm. I nhaled 
Remdesivir for Injection formulation or PTM will be administered at 
Days 1 through 5. If Day 1 assessments are performed on the same day  
as the screening assessments, procedures need not be repeated.
Participants will complete the adapted InFLUenza Patient- Reported 
Outcome (FLU -PRO©) questio nnaire dail y (Day s 1-14).
On Day s 7 and 14, assessments will include a sy mptom -directed 
physical examination. Vital signs will be measured, concomitant 
medications and AEs will be documented. Laboratory  samples will be 
obtained for safety assessments, sing le PK assessment (Day  7), and 
nasophary ngeal and orophary ngeal swab samples and saliva samples 
for SARS -CoV -2 testing and possible viral resistance testing.
On Day  28, assessments will include review of AEs and concomitant 
medications. The Day  28 follow -upassessments may  be completed by  
telephone.
If supported b y review of at least 7 -day safety data from participants in 
Parts A and B, then the Remdesivir for Inhalation Solution formulation 
will be evaluated in Part C.
Pharmacokinetic Assessments:
Sparse plasma PK assessments will be conducted in all participants at 
selected sites in Parts A and B. S parse plasma PK samples will be 
collected at Day  1 (end of nebulization,  
) and Day  3 (predose and end of nebulization ).
Up to 6 participants/group in Part A and Part B will have intensive PK 
assessments. Intensive PK samples will be collected at Day  1 and an 
additional collection, either at Day  3 or Day  5, at the following time 
points relative to the end of nebulization: 0(predose), 0.25, 0.5, 0.75, 
1, 1.5, 2, 4, and 24 hours post end of nebulization. An additional single 
PK sample will be collected on Day  7 visit for subjects who participate 
in the intensive PK assessments.
Study Part C:
Remdesivir for Inhalation Solution formulation or PTM will be 
administered Day s 1 through 5 with telehealth support as needed.
CCI
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 10 13January 2021On Day s 1, 3, 5, and 7, assessments will include a sy mptom -directed 
physical examination. Nasophary ngeal, orophary ngeal swab samples 
and saliva samples for SARS -CoV -2 testing and possible viral 
resistance testing will be collected predose with the assistance of home 
nursing on Day s 1, 3, 5, and 7. Vital signs will be performed predose 
on Day s 1, 3, and 5 and on Day  7. Concomitant medication s and AEs 
will be documented. Laboratory  samples will be obtained for safet y 
assessments predose on Day s 1, 3, 5, and 7. Plasma samples will be 
obtained for PK assessments predose on Day s 3 and 5 and Day 7 
(anytime sample) in all participants.
Participants will complete the adapted FLU -PRO©questionnaire dail y 
(Day s 1-14).
FEV 1will be performed daily  during treatment day s and will be 
performed both predose and 10 minutes postdose. Repeat FEV 1should 
be performed at 30 minutes postdose if there is > 15% reduction in 
FEV 1at 10 minutes postdose compared with the same day  predose 
FEV 1.FEV 1assessment may  also be performed if there is a clinical 
concern of bronchospasm.
On Day s 14 and 28, assessments will include review of AEs and 
concomi tant medications. The Day  14 and 28 follow -up assessments 
may be completed by  telephone.
Test Product, Dose, 
and Mode of 
Administration:In Part A and Part B , the Remdesivir for Injection formulation 
delivered b yinhalation ,will be used . In Part C ,the 
Remdesivir for 
Inhalation Solution formulation will be used .
Part A: 31 mg (nominal dose) R emdesivir for Injection administered 
via inhalation once dail y at approximately  the same time each day
Part B: 62 mg (nominal dose) R emdesivir for Injection administered 
via inhalation once dail y at approximately  the same time each day
Part C: 39mg (nominal dose) by mouthpiece of Remdesivir for 
Inhalation Solution formulation administered via inhalation once dail y 
at approximately  the same time each day
Reference Therapy, 
Dose, and Mode of 
Administration:Placebo administered via inhalation once dail y at approximately  the 
same time each day
Criteria for 
Evaluation:
Safety : Proportion of participants with treatment -emergent AEsand laboratory
abnormalities .
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-553-9020 FINAL 
Gilead Sciences, Inc. Amendment 3 
Efficacy: Change in SARS-CoV-2 viral load will be measured . A FLU-PRO © 
questio1ma ire will be utilized to report COVID-19 symptom sever ity 
and duration. Disease progress ion from baseline will be assessed by 
durat ion and change in sever ity of COVID-19 clinical symptom s and 
need for medically attended visits (MA Vs). 
Pharmacokin etics: For Parts A and B, the plasma concentrat ions of inhaled RDV and its 
metabo lites will be measured, as appropr iate. The following plasma 
PK parameters will be calculated for each analyte (RDV , GS-441524 
and GS-704277), as applicable: AUCo 24h AUC1au AUC1as1 CLs slF t,12, 
Statistical Methods: No statistical sample size/power calculation was perfonned as the 
sample size of up to approx imately 152 partici pants is deemed feasible 
and sufficient to provide a descr iptive assessment of viral kinetics, 
safety and tolerab ility, PK and disease progress ion in this study . 
CONFI DENT IAL Antiviral activity evaluation will be based on time weighted average 
change in SARS-CoV-2 viral load (defined as the AUC of viral load 
change divided by time between baseline to Day 7) and will be 
summariz ed by treatment group and each RDV group compared with 
placebo. 
Safety: 
Adverse event data will be listed by partici pant. Adverse events 
leading to study treatment discontinuation , treatment-emergent AEs, 
and serious AEs will be summariz ed by treatment, syste m organ class, 
and preferred tenn using the Medical Dictiona ry for Regulatory 
Activities (MedDRA ). 
Listings of individual partici pants laboratory results and change from 
predose values for selected laboratory values will be summari zed by 
treatment. 
Incid ence of treatment-emergent laboratory abnonna lities will be 
smmnariz ed by treatment. 
Vital signs and ECG data will be smmnariz ed by treatment. 
FEY , values will be smmnari zed by treatment. 
Listings of individua l partici pants progress ion of COVID-19 
symptom s as reported by adapted FLU-PRO © quest io1maire will be 
smmnariz ed by treatment. 
Page 11 13 January 2021 
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-553-9020 
Gilead Sciences, Inc. 
PK: FINAL 
Amendment3 
For Parts A and B, pl asma PK parameters for inhaled RDV and its 
metabo lites will be summariz ed by treatment group using descr iptive 
statistics (including mean, geometr ic mean, median, minimmn , 
maximum , and sample size). Concentrat ions of inhaled RDV and its 
metabo lites in lasma over time will be smmnariz ed. 
This study will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
includ ing archiving of essent ial documents . 
CONFI DENT IAL Page 12 13 January 2021 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 13 13January 2021GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
λz terminal elimination rate constant, estimated by linear regression of the terminal 
elimination phase of the log concentration of drug versus time curve of the drug
%AUC exp percentage of AUC extrapolated betw een AUC lastand AUC inf
AE adverse event
ALT alanine aminotransferase 
ARDS acute respiratory distress syndrome
AST aspartate aminotransferase 
ATP adenosine triphosphate
AUC area under the concentration versus time curve
AUC inf area under the concentration versus time curve extrapolated to infi nite time, calculated as 
AUC last+ (C last/λz)
AUC last area under the concentration versus time curve from time zero to the last quantifiable 
concentration
AUC tau area under the concentration versus time curve over the dosing interval
CI confidence interval
CL ss/F apparent oral clearance at steady state after administration of the drug:
CLss/F = Dose/AUC tau, where “Dose” is the dose of the drug
Clast last observed quantifiable concentration of the drug
CL cr creatinine clearance
Cmax maximum obser ved concentration of drug
COPD chronic obstructive pulmonary disease
COVID -19 coronavirus disease 2019
CoV coronavirus
CRF case report form
Ctau observed drug concentration at the end of the dosing interval
DAIDS Division of AIDS
ECG electrocardiogram
eCRF electronic case report form
EDC electronic data capture
EudraCT European Clinical Trials Database
EU European Union
EUA Emergency Use Authorization
FDA Food and Drug Administration
FEV 1 forced expiratory volume in the first second of expiration
FLU -PRO©InFLUenza Patient -Reported Outcome
FSH follicle -stimulating hormone
GCP Good Clinical Practice
Gilead Gilead Sciences, Inc.
GLPS Global Patient Safety
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 14 13January 2021IB investigator’s brochure
ICF informed consent form
ICH International Co uncil on Harmoni sation (of Technical Requirements for Registration of 
Pharm aceuticals for Human Use)
IEC independent ethics c ommittee
IND investigational new drug 
IRB institutional review board
IUD intrauterine device
IV intravenous
IXRS interactive voice/web response system
LLOQ lower limit of quantitation
MAV medically attended visit
MedDRA Medical Dictionary for Regulatory Activities
MERS Middle East respiratory syndrome
NOAEL no observed adverse effect level
PCR polymerase chain reaction
PI principal investigator
PK pharmacokinetic(s)
PT preferred term
PTM placebo -to-match
PVE Pharm acovigilance and Epidemiology
RDV remdesivir (GS -5734™)
RNA ribonucleic acid
RT-qPCR quantitative reverse transcriptase polymerase chain reaction
SAE serious adverse event 
SARS severe acute respiratory syndrome
SARS -CoV-2 severe acute respiratory syndrome coronavirus 2
SBECD sulfobutylether β -cyclodextrin sodium
SDV source data verification
SpO 2 oxygen saturation as measured by pulse oximetry
SOC standard of care
SOP standard operating procedure
SRT safety revie w team
SSR special situation report
SUSAR suspected unexpected serious adverse reaction
TEAE treatment -emergent adverse event
Tlast time (observed time point) of C last
Tmax the time (observed time point) of C max
t1/2 estimate of the terminal elimination half -life of the drug, calculated by dividing the natural 
log of 2 by the terminal elimination rate constant (λ z)
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 15 13January 2021ULN upper limit of normal
US United States
Vz/F apparent volume of distribution of the drug
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 16 13January 20211. INTRODUCTION
1.1. Background
Coronaviruses (CoVs ) are positive -sense, single- stranded, enveloped RNA viruses, many  of 
which are commonly  found in humans and cause mild sy mptoms. However, over the past 
2 decades, emerging pathogenic CoVs that can cause life-threatening disease in humans and 
animals have been identified, namel y severe acute respiratory s yndrome coronavirus 
(SARS -CoV; {de Wit 2016, Ksiazek 2003 }), Middle Eastern respiratory  syndrome coronavirus 
(MERS- CoV; {Assiri 2013 , Choi 2016, Who Mers- Cov Research Group 2013 }), and severe 
acute respiratory  syndrome coronavirus 2 ( SARS -CoV -
2), the causative agent of co ronavirus 
disease 2019 (COVID -19; {Zhu 20 20}). Coronaviruses are known to have high mutation and 
recombination rates, which may  allow them to cross species barriers and adapt to new hosts { Lau 
2015}. Bats are reservoir hosts for ma ny types of CoVs and are thought to have spread emerging 
CoVs to new species. Cross
-species transmission to animals and subsequent zoonotic 
transmission has resulted in disease in humans {de Wit 2016 }.
SARS -CoV -2, a single - stranded RNA virus, is identified as the cause of an outbreak of 
respiratory  illness that was first detected in Wuhan, China in December 2019. The virus has now 
spread globall y, resulting in a global pandemic and causing severe respiratory  illness throughout 
the world. Severe cases progress to pneumonia and multi -organ failure, which can lead to death. 
Gilead Sciences, Inc. (Gilead) has been working closely  with global health author ities to respond 
to the ongoing pandemic and to evaluate the utility  of intravenous (IV) remdesivir (RDV ; 
GS-5734™) as a treatment option for COVID- 19. Supported by  Phase 3 clinical studies ,IV
RDV has been approved for treatment of COVID -19 in Japan ,the 
European Union (EU) , the 
United States (US) , and other countries.
1.2. Remdesivir ( RDV ;GS-5734) for Inhaled Administration
Remdesivir is being developed by  Gilead and is formulated for IV administration and for 
administration via nebulization.
1.2.1. General Informat ion
Remdesivir is an adenosine nucleotide prodrug that distributes into cells where it is metabolized
to form the pharmacologically  active nucleoside triphosphate metabolite. Metabolism of
remdesivir to remdesivir triphosphate has been demonstrated in mult iple cell ty pes. Remdesivir
triphosphate acts as an analog of adenosine triphosphate (ATP) and competes with the natural
ATP substrate for incorporation into nascent RNA chains by the SARS -CoV -2 RNA -dependent
RNA poly merase, which results in inhibition of viral replication .
For further information on RDV , refer to the investigator’s brochure (IB) for RDV . 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 17 13January 20211.2.2. Additional Clinical Studies of Remdesivir
1.2.2.1. GS-US-553- 9018 Inhaled Remdesivir Phase 1a Study
Study  GS
-US-553- 9018 is an ongoing randomized, blinded, placebo-controlled, single- and 
multiple -dose study  with staggered dose escalation and adaptive dose selection evaluating 
inhaled RDV. In each cohort, 10 healthy  male and nonpregnant, nonlactating, female volunteers, 
aged 18 through 45, inclusive are rando mized 4:1 to receive inhaled RDV or placebo- to-match
(PTM) . Participants received single doses of 12.5 mg, 31 mg, and 62 mg of Remdesivir for 
Injection formulation via nebulization in Cohorts 1, 2, and 4 respectivel y or multiple doses of 
31mg or 62 mg each day for 5 days in Cohorts 3 and 5. Cohorts 1 through 5 received 
Remdesivir for Injection formulation via nebulization, and Cohort 6 received Remdesivir for 
Inhalation Solution formulation. Safety  data as of 10 September 2020 included all participants in 
Cohorts 1 through 5. All AEs were mild or moderate . There were no deaths, serious adverse 
events ( SAEs ), pregnancies ,or study  drug discontinuations.
Preliminary plasma PK data in healthy  participants are available following administration of 
inhaled Remdesivir for Injection formulation as single nominal doses of 12.5 mg to 62 mg (2 mg 
to 10 mg deposited), and as multiple nominal doses of 31 mg (5 mg deposited) and 62 mg 
(10mg deposited) for 5 day s. Following single nominal dose administration of 12.5 mg, 31mg,
and 62 mg inhaled Remdesivir for Injection formulation, maximal concentrations of RDV and 
GS-704277 were achieved at the end of nebulization or within 30 minutes after the end of 
nebulization; plasma concentrations declined rapidly  thereafter a nd were undetectable (below the 
limit of quantitation) at 2 hours and 4hours postdose for RDV and GS -704277, respectivel y. 
GS-441524 concentrations peaked at 3 to 4 hours postdose and remained detectable up to 
48hours postdose in most participants. Approximately  dose proportional increases in the 
exposures of RDV and the metabolites were observed following 12.5 mg , 31 mg and 62 mg 
single dose administration. Following multiple dose administration, no accumulation was noted 
for RDV and GS -704277, consisten
t with the short half-lives. Accumulation ratios of GS-441524 
ranging from 1.2 to 1.6 were observed on Day  5 consistent with its longer half -life ranging from 
11.2 hours (31 mg single dose) to 28.6 hours ( 62mg multiple doses, Day  5).
Overall, the observe d steady -state plasma exposures at the 31 mg and 62 mg nominal dose were 
substantially  below those observed with the 100 mg IVclinical dose at steady -state (IV 
exposures were approximately  101 and 70- fold higher for RDV, 11 and 6.5 -fold higher for 
GS-704277, and 16 and 8.5 -fold higher for GS -441524 compared with the 31 mg , and 62 mg
nominal dose of inhaled Remdesivir for Injection formulation, respectively ). These results were 
similar to those observed in the nonclinical inhaled Remdesivir for Injection fo rmulation study  in 
African green monkey s. Comparison of the preliminary  human and nonclinical African green 
monkey  PK data indicate that it is reasonable to expect thatthe 31 mg and 62 mg human nominal 
inhaled dose s(5 mg and 10 mg deposited) may  produce similar
, or exceeding GS-443902 
(triphosphate) levels in respiratory  tissues as the 100 mg human IV dose.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 18 13January 20211.2.3. Rationale for This Study
The evaluation of inhaled RDV as a treatment forCOVID -19is supported by clinical data from 
studies of IV RDV in patients with COVI D-19, inhaled administration of RDV in health y 
volunteers, and nonclinical characterization of 
inhaled administration in PK, toxicology , and 
efficacy  studies .
Remdesivir for treatment of COVID -19 administered by  IV infusion is now approved in Japan, 
the EU, US, and numerous countries globally . Emerging data suggest that upper airway  disease 
precedes lower airway  and lung disease in individuals infected with SARS -CoV - 2 {Wolfel 
2020}. Delivery  of RDV by  inhalation could enable antiviral activit y in the respiratory tract 
while achieving lower s ystemic drug exposures, potentially offering an option in 
non-hospitalized patients, and enabling use of RDV in patients who are not currentl y eligible for 
IV administration of RDV. Inhalation is a less invasive route of administration which will 
support outpatient administration. Furthermore, drug suppl y ma y be more efficientl y utilized as 
there is potentially  less total active 
pharmaceutical ingredient needed for each dose b y inhalation 
versus IV administration. The current ly ophilized clinical formulation of IV RDV, Remdesivir
for Injection, 100 mg, is suitable for nebulization. Additionally , a new formulation with a 
reduced conte nt of sulfobuty lether β -cyclodextrin sodium (SBECD), Remdesivir for Inhalation 
Solution, 40 mg, is being evaluated in aPhase 1a study . 
Data from nonclinical studies evaluating inhalation of RDV indicate minimal respiratory  tract 
findings in a single dose PK study  in African green monkey s, and a 7- day rat repeat- dose toxicity  
study . These studies demonstrate the localized delivery of RDV and formation of the active 
triphosphate, GS -443902, in respiratory  tissues with lower sy stemic exposure to RDV and 
meta bolites.
This study  will evaluate the potential for a short course of nebulized RDV to prevent progression 
of COVID -19 in participants with earl y infection. The doses selected are anticipated to result in 
similar levels of triphosphate in the lung as that which results from IV administration.
Remdesivir by  IV administration has a favorable safet y and efficacy profile. Enrollment of this 
study  in multiple parts will allow an initial assessment of safet y and antiviral kinetics of 
nebulized RDV in ear ly stage COVID -19 patients in Parts A and B of the study . Part C of the 
study  will allow for evaluation of safet y and efficacy  of an inhaled RDV formulation with 
reduced SBECD content ( Remdesivir for Inhalation Solution formulation via a mouthpiece ). The 
use of a mouthpiece allows more drug to be administered over a shorter time period compared to 
a facemask and is more suitable for self/at -home administration.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 19 13January 20211.3. Rationale for the Dose Selection
Remdesivir has been approved for the treatment of COVID -19in Japan, the EU, and the US at 
an initial dose of 200 mg IV followed b y 100 mg IV for the next 4 or 9 days. This protocol 
proposes investigation of a new route of administration through the respiratory  tract to deliver 
drug directl y to the primary site of infe ction while reduc ingoverall sy stemic exposure.
Safety , tolerability , and PK of RDV administered via inhalation are being evaluated in an 
ongoing Phase 1a study  in healthy  participants (GS -US-553-9018). Two different RDV 
formulations, Remdesivir for Inject
ion formulation and Remdesivir for Inhalation Solution 
formulation, were evaluated in this study  at the nominal doses up to 62 mg (estimated 10 mg 
deposited dose, administered using LC®Sprint (PARI  Respiratory  Equipment, I nc.)equipped 
with sealed facemask and an exhaust filter, 16.1% to 17% device efficiency ) once daily  for 
5days. Safet y and preliminary PK data are available for the Remdesivir for Injection 
formulation, and PK and safet y results for Remdesivir for Inhalation Solution formulation are 
forthcoming. An amendment to protocol GS-US-553-9018 is ongoing to generate additional 
safet y and PK data for LC Sprint equipped with mouthpiece, and Remdesivir for Inhalation 
Solution formulation. Th is additional cohort isplanned to run in parallel to Part C of the 
GS-US-
553-9020 study , and together will inform on the Phase 3 dose selection for inhaled RDV . 
Both formulations were well tolerated in the healthy  volunteer study  up to 62 mg nominal dose 
(10 mg deposited). Preliminary  data are discussed in Section 1.2.2.1. 
Based on these results ,31 mg and 62 mg doses are proposed for evaluation in Parts A and B of 
the current study , respectively . Briefl y, a nominal do se of 31 mg Remdesivir for Injection 
formulation (estimated 5 mg deposited dose; utilizing 16.1% device efficiency ) for 3 or 5 day s is 
proposed for evaluation in Part A. This dose is predicted to achieve similar concentrations of the 
active GS -443902 in re spiratory  tissues as those expected following a 100 mg human IV dose. A 
higher nominal dose of 62 mg (estimated 10 mg deposited dose; utilizing 16.1% device 
efficiency ), which may  provide increased efficacy when administered to patients, is proposed for 
Part B. In both Parts, RDV will be administered using LC Sprint equipped with sealed facemask 
and an exhaust filter . 
Part C: 
Remdesivir for Inhalation Solution formulation and anew device configuration of L C Sprint 
utilizing a mouthpiece for drug delivery will be evaluated in Part C. This new formulation 
contains reduced levels of 
an excipient ,SBECD (7.5% after reconstitution , as compared to 15% 
for Remdesivir for Injection formulation ), which may  offer improved safety  when RDV is 
administered via inhalation. Both the new formulation and the new device configuration are 
being evaluated in healthy  participants: Cohort 6 ( 60 mg Remdesivir for Inhalation Solution 
formulation or placebo, for 5 day s, inhaled via sealed facemask) and Cohort 7 (39 mg 
Remdesivir for Inhalation Solution formulation or placebo, single dose, inhale d via mouthpiece) . 
In alignment with the doses evaluated in the healthy volunteers study , the nominal dose in Part C 
is projected to be 39mg (estimated 10mg deposited dose; utilizing 25.6% mouthpiece 
configuration efficiency ).
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 20 13January 2021The proposed dose s for evaluation in Part A, B, and C are anticipated to be safe and efficacious, 
based on the cumulative clinical and nonclinical information available to date (
Section 1.2.2.1
and inhalation I B
). Estimated dose margins based on mg/g lung weight at the lowest and highest 
nominal doses evaluated in this study  are 5.2- and 2.6 -fold, respectivel y (inhalation I B ).
Duration of 3 to 5 day s of dosing will be evaluated in this study . The 5 -day dosing duration is the 
recommended IV remdesivir duration for treatment of COVID -19 requiring hospitalization and 
not requiring invasive mechanical ventilation and/or e xtracorpore al membrane ox ygenation
{VEKLURY 2020 }.Shorter treatment duration of IV RDV for 3 day s is currentl y being 
evaluated in an outpatient 
study (GS-US- 540- 9012 )in COVID -19 patients at risk for disease 
progression.
1.4.
Risk/Benefit Assessment for the Study
Potential risks of a participant’s study  involvement include unknown adverse events (AEs) due 
to inhaled RDV . Strategies to mitigate these risks include close monitoring of participant’s
clinical status andlaboratory  testing . Parameters for discontinuation of the study  treatment due to 
AEs will be well defined and closel y followed.
Transient, Grade 
≤2, treatment -emergent elevations in alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) were observed with dail y IV RDV administration in Phase 1 
studies in healthy  volunteers. Transaminases increased is a listed adverse drug reaction to RDV . 
However, due to the reduced systemic exposure to RDV compared to the IV regimen, it is 
anticipated that there will be a lowe r effect on ALT and AST. Nonetheless, liver function testing 
will be closely  monitored during the study .
Remdesivir contains SBECD, an approved excipient. In nonclinical species, SBECD 
administration has been associated with kidney  vacuolation and hy pertro phy. However, 
nonclinical inhalation toxicology studies and available inhaled clinical data with SBECD support 
its use in the RDV clinical formulation .
Participants may or may  not clinically  benefit from participation in the study. If efficacious, 
benefits might include shorter duration or lower severity  of COVID -19 sy mptoms or reduced 
progression to severe disease. They  may  also benefit from increased observations and 
evaluations by  health care professionals. D ata from this study  may  support further evalua tion of 
inhaled RDV in patients with COVI D-19.
During a pandemic, additional potential risks to participants may include adequate study  
treatment availabilit y, interruptions to the study visit schedule, and adherence to 
protocol -specified safety  monitoring or laboratory  assessments. Refer to Appendix 2for further 
details on the risks and risk mitigation strategy .
Considering the above, the benefit -risk balance for this study  is considered positive.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 21 13January 20211.5. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-553-9020 
Gilead Sciences, Inc. 
2. OBJECTIVES 
The primary object ive of this study is: FINAL 
Amendment3 
• To character ize the impact of inhal ed RDV on SARS-CoV-2 viral load in partici pants with 
early stage COVID-19 
The secondary object ives of this study are: 
• To evaluate the safety and tolerability of inhaled Re mdesivir for Injection fonnu lation in 
partici pants with early stage COVID-19 
• To evaluate the PK of inhaled Re mdesivir for Injection fonnu lation and its metabolit es in 
partici pants with early stage COVID-19 in Parts A and B 
• To character ize and evaluate disease progress ion from baseline 
• To character ize the efficac y, safety, and tolerability of Remdesivir for Inhalation Solution 
fonnu lation administere d with a mouthpi ece in Part C of the study 
I 
I 
CONFI DENT IAL Page 22 13 January 2021 
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-553-9020 
Gilead Sciences, Inc. 
3. STUDY DESIGN 
3.1. Endpoints 
The primary endpoint of this study i s: FINAL 
Amendment3 
• Time weighted average change in SARS-CoV-2 viral load which is de fined as AUC of viral 
load change divided by time between base line through Day 7 
The secon dary endpoints of this study are: 
• Proportion of partic ipants with treatment-emergent AEs (TEAEs) and laboratory 
abnonna li ties 
• Proportion of partic ipants with TEAEs leading to study treatment discont inuation 
• Compos ite of all-cause medi cally atten ded visi ts (MA Vs) (medi cal visi ts atten ded in person 
by the participant and a h ealth care professional) or death by Day 28 
• Compos ite of COVID- 19 related MA Vs (med ical visi ts atten ded in person by the participant 
and a h ealth care professional) or death by Day 28 
• Proportion of participants hosp italized by Day 28 
• Character ization of the plasma concentrat ions of inhaled RDV and its metabo lites inclu ding 
AUC o 24h, AUC 1as1, CLss !F, t112, V vF, Cmax, Tmax, C1as1, T1as1, AUC 1au, ')....L., and C1au (Parts A and B 
only) 
• Change in SARS-CoV-2 viral load from base line to Day 5 
• Change in SARS-CoV-2 viral load from base line to Day 7 
• Change in SARS-CoV-2 viral load from base line to Day 14 ( Parts A and B only) 
• Time to negative SARS-CoV-2 polymerase chain reaction (PCR) 
• Time to alleviation (mild or absent) of base line COVID- 19 symptom s as reporte d on the 
COVID- 19 ad apted InFLU enza Patient-Reported Outcom e (FLU-PRO ~ questionna ire 
I 
I 
CONFI DENT IAL Page 23 13 January 2021 
Remde sivir (RDV; GS-5734 T") 
Protocol GS-US-553-9020 
Gilead Sciences, Inc. 
I 
I 
I 
I 
3.2. Study Design FINAL 
Amendment3 
This study is a random ized, blinded, placebo-contro lled, multic enter study of inhaled RDV in 
partici pants with early stage COVID-19 infect ion. In Parts A and B of the study, eligible 
partici pants will be random ized in equa l proport ions to 1 of 3 treatment groups . 
Part C of this study is a random ized, blinded , placebo-contro lled, multic enter study of 
Remdesivir for Inhalation Solution fonnu lation in participants with early stage COVID-19 
infect ion. Eligible partici pants will be random ized in a 3: 1 ratio to 1 of 2 treatment groups to 
receive Remdesivir for Inhalation Solution fonnu lation or PTM admini stered by mouthpi ece. 
The tenn "inhaled remdes ivir" refers to both the Remdesivir for Injection fonnu lation and 
Remdesivir for Inhalation Solution fonnu lation when administered via nebu lization using the LC 
Sprint. 
3.3. Study Treatments 
The study will feature multipl e parts: Part A, Part B, and Part C. The pla1med nominal doses are 
provided below by treatment group . 
In Part A, approx imately 36 partic ipants who meet all eligib ility criteria will be random ized in a 
1: 1: 1 ratio into one of the following 3 treatment groups: 
Treatment Group 1: 31 mg inhaled Remdesivir for Injection fonnu lation daily for 5 days 
Treatment Group 2: 31 mg inhaled Remdesivir for Injection fonnu lation daily for 3 days 
followed by PTM daily for 2 days 
Treatment Group 3: PTM daily for 5 days 
CONFID ENTIAL Page 24 13 Januar y 2021 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 25 13January 2021Part A
In Part B, if supported by Phase 1a data in healthy  volunteers, an additional 36 participants who 
meet all eligibility  criteria may  be randomized in a 1:1:1 ratio into one of the following treatment 
groups:
Treatment Group 4: 62 mg inhaled Remdesivir for Injection formulation daily  for up to 5 day s
Treatment Group 5: 62 mg inhaled Remdesivir for Injection formulation daily  for up to 3 day s 
followed b y PTM through Day 5
Treatment Group 6: PTM daily  for 5 day s
Part B
In Parts A and B, a t in-clinic screening, after the participant has provided informed consent, 
assessments will include but are not limited to the following: demographic and baseline 
characteristics, medical history , and concomitant medications will be documented. B ody weight 
and height will be measured. A urine pregnancy  test will be performed for women of 
childbearing potential. Vital signs including heart rate, temperature, blood pressure, and SpO 2
will be recorded. A complete phy sical examination will be performe d.
Participants with PCR -confirmed COVID- 19 who enroll in the study  will return to clinic daily  on 
Days 1through 5 for study  treatment administration and clinical assessments. Participants will 
return to clinic on Day s 7 and 14 for follow -up clinical asse ssment and undergo a Day  28 
follow -upwhich may  be completed b y telephone .
n = 36 
Randomized 
1: 1: 1 
n = 36 
Randomized 
1:1:1 n = 12 I 
n = 12 I 
n = 12 I 
n = 12 I 
n = 12 I 
n = 12 I Inhaled Remdesivir for Injection formulation daily 
for 5 days , 31 mg nominal dose 
Inhaled Remdesivir for Injection formulation daily 
for 3 days, 31 mg nominal dose 
PTM daily for 5 days 
Inhaled Remdesivir for Injection formulation daily 
for up to 5 days , 62 mg nominal dose 
Inhaled Remdesivir for Injection formulation daily 
for up to 3 days , 62 mg nominal dose 
PTM daily for 5 days 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 26 13January 2021Part C
Part C of the study  will include an expanded safety  and efficacy  assessment of an additional 
80participants . Participants in Part C will be enrolled after review of preliminary safet y data 
from Parts A and B through at least Day  7. A pproximately  80 participants will be randomized 
3:1 to 1of 2 treatment groups:
Treatment Group 7 : 39mg Remdesivir for Inhalation Solution formulation once dail y for 
5days by mouthpiece
Treatment Group 8 : PTM daily  for 5 day s by mouthpiece
At screening, after the participant has provided informed consent, assessments will include but 
are not limited to the following: demographic and baseline charact eristics, medical history , and 
concomitant medications will be documented. Body  weight and height will be measured. A urine 
pregnancy  test will be performed for women of childbearing potential. Vital signs including heart 
rate, temperature, blood pressure, and SpO 2will be recorded. A complete physical examination 
will be performed.
In Part C , participants with nucleic acid testing or direct antigen testing -confirmed COVID -19 
who enroll in the study  will be administered Remdesivir for Inhalation Solution fo rmulation or 
PTM on Day s 1 through 5. Clinical assessments may  be conducted athome with the assistance 
of home nursing on Day s1,3, 5,and 7 . Participants will undergo Day s 14 and 28 telephone 
contact follow -ups.
3.4. Safety Review Team
A safet y review team (SRT) will be established to assess safet yandmake decisions on dose 
selection and duration before initiating Part C .
The SRT will include the Gilead medical monitor. Other members of the SRT may  include 
representatives from 
Global Patient Safety  (GLPS) ( formerly  known as Pharmacovigilance and 
Epidemiology  [PVE ]), Clinical Operations, Biostatistics, and/or Clinical Pharmacology . 
Additional members may be invited to participate if additional expertise is needed. The medical 
monitor serves as the chair of th e SRT. A nSRT charter (or similar document) will be agreed 
upon by  all SRT members prior to the first SRT meeting.
n = 80 
Randomized 
3:1 n = 60 
n = 20 I 
I Remdesivir for Inhalation Solution formulation daily 
for 5 days by mouthpiece , 39 mg nominal dose 
PTM daily for 5 days by mouthpiece 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 27 13January 2021The data reviewed at the SRT meetings to make optimal dosing and duration decisions will be 
defined in the SRT charter, including safet y and nonclinical toxicity  data . The quality  control 
checks performed on the data reviewed and used for making optimal dosing and duration
decisions will also be described in the SRT charter .
Source data verification may  not be performed prior to themeetings. Alternative data qualit y 
control checks that are performed on data used to make optimal dosing and duration decisions 
are described in the SRT charter .
3.5. Duration of Treatment
In Parts A and B, participants will receive stud y treatment with inhaled Remdesivi r for Injection 
formulation or PTM for 5 day s.The duration of nebulization for Remdesivir for Injection is 
approximately  17 minutes for a nominal dose of 31 mg Remdesivir for Injection formulation
RDV and approximately  34 minutes for a nominal dose of 62 mg inhaled Remdesivir for 
Injection formulation .
In Part C, participants will receive stud y treatment with Remdesivir for Inhalation Solution or 
PTM for 5 day sviaa mouthpiece . The duration of nebulization for Remdesivir for Inhalation 
Solution is approx imately 19 minutes for a nominal dose of 3 9mg Remdesivir for Inhalation 
Solution formulation through a mouthpiece.
3.6. Discontinuation Criteria
Study  treatment dosing in an individual subject will be placed on hold and may be discontinued 
following a review of all available clinical data by  the medical monitor and discussion with the 
investigator, 
if any  of the following occurs:
Any SAE or ≥ Grade 3 AE suspected to be related to RDV
Any elevations in ALT ≥ 5  upper limit of normal ( ULN ); or ALT ≥ 3  ULN and total 
bilirubin ≥ 2ULN, confirmed b y immediate repeat testing
FEV 1decline of > 15% at 30 minutes postdose compared with same day  predose FEV 1
Discontinuation of study  medication is not a seriousness criterion.
Subjects, who discontinue the study  medication , should be encouraged to remain in the study  and 
attend study  visits as described in Section 6(Study  Procedures )
.
3.7. End of Study
The end of this study  will be the last subject’s last observation (or visit).
3.8. Posts tudy Care
The long- term care of the participant will remain the responsibility  of their primary  treating 
physician. Remdesivir is being supplied with curative intent. There is no provision for poststudy  
availability .
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-553-9020 
Gilead Sciences, Inc. 
3.9. Source Data FINAL 
Amendment3 
The source data for this study w ill be obtained from electron ic data capture (EDC), centra l 
laboratory, local laboratory, and spec ialty laboratory (for PK d ata). 
CONFI DENT IAL Page 28 13 January 2021 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 29 13January 20214. SUBJECT POPULA TION
4.1. Number of Subjects an d Subject Selection
In Part A and Part B, a pproximately  36 participants will be enrolled in each part . Approximately  
80 participants will be enrolled in Part C. Participants in Part C may receive study  treatment in a 
home setting.
4.1.1. Subject Replacement
Subje cts who discontinue prior to the end of stud y will not be replaced .
4.2.
Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study :
1) Willing and able to provide written informed consent, or with a legal representative who can 
provide informed consent
2)Aged ≥ 18 y ears
3)SARS -CoV -2 infection first confirmed b y PCR (Parts A and B) or b y nucleic acid testing or 
direct antigen testing (Part C) with sample collected ≤ 4days prior to randomization
4)COVID -19symptom onset ≤ 7 day s prior to randomization
5)SpO 2> 94% on room air
6)Participants of childbearing potential who engage in heterosexual intercourse must agree to 
use protocol specified method(s) of contraception as described i n Appendix 5
4.3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study :
1)Ongoing or prior p articipation in any  other clinical trial of an experimental vaccine or 
treatment for COVID -19
2) Prior or current hospitalization for COVID - 19or need for hospitalization
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 30 13January 20213) T reatment of COVID -19 with other agents with actual or possible direct antiviral activit y 
against SARS -CoV -2including IV RDV or administration of any  SARS -CoV -2 (or 
COVID -19) vaccine
a)Patients chronicall y administered chloroquine or hydrox ychloroquine for any  reason are 
to be excluded 
4)Requiring ox ygen supplementation
5)Positive pregnancy  test (Appendix 5)
6)Breastfeeding female
7)Known hy persensitivity  to the study  treatment , itsmetabo lites, or formulation excipient
8) P re-existing pulmonary  conditions such as chronic obstructive pulmonary  disease or asthma 
(Part sA and B only )
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 31 13January 20215. INVESTIGA TIONAL  MEDI CINAL  PRODUCTS
5.1. Randomization, Blinding ,and Treatment Codes Access
5.1.1. Randomization
In Part A, approximately  36 participants who meet eligibility  criteria will be randomized in a 
1:1:1ratio to receive either of two inhaled 31 mg RDV regimens or PTM starting on Day  1using 
an interactive voice/web response s ystem ( IXRS)andassigned a subject number . InPart B , an 
additional 36 participants who meet eligibility  criteria will be randomized in a 1:1:1 ratio to 
receive either of two inhaled 62 mg RDV regimens or PTM starting on Day 1 using an I
XRS and 
assigned a subject number.
In Part C, approximately  80participants will be randomized 3:1 to 1 of 2 treatment groups to 
receive either: Remdesivir for Inhalation Solution formulation (nominal dose of 39mgto 
achieve 10 mg deposited dose) administered b y mouthpiece or PTM administered by  mouthpiece
starting on Day  1 using an IXRS and assigned a subject number .
5.1.2. Blinding
Thestudy will be sponsor unbl inded
. During the randomized phase, Gilead personnel and site 
pharmacist will be unblinded while the investigational site(s) and subjects participating in the 
study  will remain blinded. To mitigate the risks of inadvertentl y releasing the treatment 
informa tion, certain Gilead staff will only  be provided with the unblinded information when 
there is a need to access such information for data anal ysis to support internal dose 
determination . Should Gilead staff receive unblinding information, they  will maintain the 
confidentiality  of the unblinded information, and will not communicate the information to 
blinded sites, or subjects as specified in Gilead standard operating procedures ( SOPs).
During the randomized phase , subjects and all study  site personnel directly involved in the 
conduct of the stud y will be blinded to treatment assignment . Specified personnel may  be 
unblinded based on their study  role. Study  treatment will be dispensed by  an unblinded
pharmacist to the subjects. 
Monitor s, who will oversee activities relating to study  drug, such as 
drug storage, drug accountability , and verify ingrandomization schedules as documented in the 
Study  Monitoring Plan, will remain unblinded. Other non-Gilead personnel who are responsible 
for ensuring data integrit y or participant safety may be unblinded as well. The Pharmacokinetics 
File Administrator, or designee, in Bioanaly tical Operations and/or Clinical Data Management,
who facilitates the data transfer of PK files between Gilead and vendors, will remain unbli nded . 
Individuals in Clinical Packaging & Labeling or Clinical Supply  Management who have an 
Unblinded Inventory  Manager role in the IXRS system for purposes of study  treatment inventory  
management will remain unblinded. Individuals in Clinical Virology  responsible for the selection 
of samples for sequencing and/or interpretation of sequencing data will remain unblinded. 
Individuals in GLPS responsible for safety  signal detection, IND s afety reporting and/or 
expedited reporting of suspected unexpected serious adverse reactions (SUSARs) may  be 
unblinded to individual case dat a and/or group level summaries. External (ie, contract research 
organizations) B iostatisticians and Programmers may beunblinded for d ata monitoring purposes .
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 32 13January 2021Regulatory  Quality  and Compliance personnel in Research and Development may  also be 
unblinded for purposes of supporting Quality  Assurance activities and/or Regulatory  Agency  
inspections.
5.1.3. Procedures for Breaking Treatment Codes
In the event of a medical emergency  where breaking the blind is required to provide medical care 
to the subject, the investigator may  obtain treatment assignment for that subject. Gilead 
recommends but does not require that the investigator contact the Gilead medical monitor before 
breaking the blind. Trea tment assignment should remain blinded unless that knowledge is 
necessary  to determine subject emergency  medical care. The rationale for unblinding must be 
clearl y explained in source documentation along with the date on which the treatment 
assignment was obtained. The investigator is requested to contact the Gilead medical monitor 
promptly  in case of an y treatment unblinding .
Blinding of stud y treatment is critical to the integrity of this clinical study and therefore, if a 
subject’s treatment assignment is disclosed to the investigator, the subject will have study  
treatment discontinued. All subjects will be followed until study  completion unless consent to do 
so is specificall y withdrawn by the subject.
5.2. Description and Handling of Remdesivir
5.2.1. Formulation
Remdesivir for Injection, 100 mg, is a preservative -free, white to off -white or y ellow, 
lyophilized solid containing 100 mg of remdesivir that is to be reconstituted with 19 mL  of 
sterile water for injection prior to administration by inhalation through a n
ebulizer. Following 
reconstitution, each vial contains a 5 mg/mL remdesivir concentrated solution with sufficient 
volume to allow withdrawal of 20 mL (100 mg of remdesivir). Remdesivir for Injection, 100 mg, 
is supplied as a sterile product in a single -use, 30 mL , Type 1 clear glass vial. I n addition to the 
active ingredient, Remdesivir for Injection, 100 mg contains the following inactive ingredients: 
SBECD, water for injection, hy drochloric acid, and sodium hy droxide. Hy drochloric acid and 
sodium hy droxid e are used to adjust the formulation to a pH of 3.0 to 4.0.
The supplied Placebo- to-Match Remdesivir for Injection, 100 mg, (PTM Remdesivir for 
Injection, 100 mg) is identical in phy sical appearance to the active formulation and contains the 
same inactive ingredients.
Remdesivir for Inhalation Solution, 40 mg, is a preservative -free, white to off -white or yellow, 
lyophilized solid containing RDV that is to be reconstituted with 8.4 mL  of sterile water for 
injection prior to administration by  inhalation through a nebulizer. Following reconstitution, each 
vial contains a 5 mg/mL RDV solution with sufficient volume to allow withdrawal of 8 mL 
(40mg of RDV ). Remdesivir for Inhalation Solution, 40 mg, is supplied as a sterile product in a 
single -use, 20 mL , Type I clear glass vial. In addition to the active ingredient, Remdesivir for 
Inhalation Solution, 40 mg, contains the following inactive ingredien ts: SBECD, water for 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 33 13January 2021injection, hy drochloric acid, and sodium hy droxide. Hy drochloric acid and sodium hy droxide are 
used to adjust the formulation to a pH of 3.0 to 4.0.
The supplied Placebo -to-Match Remdesivir for Inhalation Solution, 40 mg, (PTM Remdesiv ir 
for Inhalation Solution, 40 mg) is identical in ph ysical appearance to the active formulation and 
contains the same inactive ingredients.
Detailed information regarding stud y treatment administration and reconstitution instructions are 
included in a pha rmacy  manual provided to the investigator.
5.2.2. Packaging and Labeling
Remdesivir for Injection , 100 mg, and placebo areprovided in 30 mL  glass vials enclosed with 
rubber stopper and aluminum seal with a poly propy lene flip -off cap. Following reconstitution, 
each single -use vial contains sufficient volume to allow withdrawal of 20 mL  (100 mg RDV or 
placebo).
Remdesivir for Inhalation Solution, 40 mg, and placebo are provided in 20 mL  glass vials 
enclosed with rubber stopper and aluminum seal with a poly propyleneflip-off cap. Following 
reconstitution, each single -use vial contains sufficient volume to allow withdrawal of 8 mL 
(40mg RDV or placebo).
Remdesivir for Injection , 100 mg, Remdesivir for Inhalation Solution, 40 mg, and their matching 
placebo vials to be distributed to study  center sandshall be labeled to meet applicable 
requirements of the US FDA and/or local regulations.
Sufficient quantities of Remdesivir for Injection , 100 mg, Remdesivir for Inhalation Solution, 
40mg,and their matching placebo vial s will be shipped to the investigator or qualified designee 
from Gilead Sciences Clinical Supplies Management (or its designee).
5.2.3. Storage and Handling
Remdesivir for Injection, 100 mg, and PTM Remdesivir for Injection, 100 mg, vials should be 
stored below 3
0 °C prior to use .Remdesivir for Injection and placebo vials are recommended to 
be reconstituted and diluted within the same day  as administration. Remdesivir for Injection and 
placebo vials do not contain any  preservative sand areintended for single -use. Any unused 
Remdesivir for Injection and placebo material should be discarded.
The total storage time of reconstituted solution containing Remdesivir for Injection or placebo 
should not exceed 4 hours at room temperature (20 °C to 25 °C) or 24 hours at re frigerated 
temperature (2 °C to 8 °C). Any  unused R emdesivir for Injection and placebo material should be 
discarded.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 34 13January 2021Remdesivir for Inhalation Solution, 40 mg, and PTM Remdesivir for Inhalation Solution, 40 mg, 
vials should be stored below 30 °C prior to u se. Remdesivir for Inhalation Solution and placebo 
vials are recommended to be reconstituted and diluted within the same day as administration , if 
feasible . Remdesivir for Inhalation Solution and placebo vials do not contain any  preservatives 
and are intended for single -use. An y unused Remdesivir for Inhalation Solution and placebo 
material should be discarded.
The total storage time of reconstituted solution containing Remdesivir for Inhalation Solution or 
placebo should not exceed 4 hours at room temperat ure (20 °C to 25 °C) or 7 day sat refrigerated 
temperature (2 °C to 8 °C). Any  unused Remdesivir for Inhalation Solution and placebo material 
should be discarded.
5.3. Dosage and Administration of Remdesivir
Remdesivir for Injection, 100 mg, and Remdesivir for Inhalation Solution, 40 mg, will be 
provided b y Gilead. Remdesivir for Injection will be administered in Parts A and B of the study  
and Remdesivir for Inhalation Solution will be administered in Part C of the study . 
All study  treatments will be administered at approximately  the same time each day .
In Parts A and B, RDV or PTM will be administered as an aerosolize d solution by  inhalation 
through a sealed facemask coupled with a nebulizer with a single inlet/outlet and exhaust filter.
Theduration of nebulization is approximately  17 minutes for a nominal dose of 31 mg inhaled 
Remdesivir for Injection. The duration of nebulization is approximately  34minutes for a nominal 
dose of 62 mg inhaled R emdesivir for Injection .
In Part C, RDV or PT M will be administered as an aerosolized solution by inhalation through a 
mouthpiece coupled with a nebulizer with a single inlet/outlet. The duration of nebulization is 
approximately  19minutes for a nominal dose of 3 9mg Remdesivir for Inhalation Solutio n.
Detailed information regarding stud y treatment administration and reconstitution instructions can 
be found in the pharmacy manual.
5.4. Dispensing, Accountability, and Disposal or Return ofStudy T reatment
The investigator (or designee, eg, stud y center phar macist) will acknowledge receipt of the study  
treatment (after reviewing the shipment’s content and condition) from Gilead (or designee). The 
investigator will maintain an accurate inventory  of all study  drugs. For Parts A and B, each dose 
of the study  treatments administered at the study  center will be administered by  qualified study  
center staff. The dose of study  treatments administered to subjects in the clinic under the 
supervision of staff will be accuratel y recorded on the Study  Drug Accountabilit yform provided 
by Gilead (or on equivalent documentation maintained by  the study  center), which indicates the 
date and quantit y of each dosage formulation dispensed to individual subjects. For Part C, each 
dose of study  treatment may  be administered at ho me or in
-clinic. During study  drug 
dispensation, the dose of study treatment will be accurately  recorded on the Study  Drug 
Accountability  form provided by  Gilead (or on equivalent documentation maintained by  the 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 35 13January 2021study  center), which indicates the date and quantity  of each dosage formulation dispensed to 
individual subjects. I f study  drug is administered at the home setting, a home health service 
provider will be available to provide supervision either in- person or via tele health. All 
information and documen tation related to home administration of study  drug will be provided to 
the investigator b y the home health provider, wherever applicable, in a timely  manner.
Gilead recommends that used and unused stud y treatment should be destroyed at the site. If the 
site has an appropriate SOP for drug destruction as determined by  Gilead, the site may  destroy  
used (empt y or partially empty) and unused stud y treatment supplies in accordance with that 
site’s approved SOP. A copy  of the site’s approved SOP will be obtained forthe electronic Trial 
Master File . If study  drug is destro yed onsite, the investigator must maintain accurate records for 
all study  treatments destroy ed. Records must show the identification and quantity  of each unit 
destroy ed, the method of destructio
n, and the person who disposed of the study  treatment . Upon 
study  completion, copies of the study  treatment accountability  records must be filed at the site. 
Another cop y will be returned to Gilead.
If the site does not have an appropriate SOP for drug des truction, used and unused study  
treatment supplies are to be sent to the designated disposal facility  for destruction. The study  
monitor will provide instructions for return.
The study  monitor will review study  treatment supplies and associated records at periodic 
intervals.
For both disposal options listed above, the study  monitor must first perform drug accountability  
during a remote monitoring visit.
5.5. Prior and Concomitant Medications
Due to antagonism observed in vitro with RDV , use of chronically  admini stered chloroquine or 
hydroxychloroquine for any  reason is exclusionary. 
Concomitant treatment with other agents with actual or possible direct antiviral activity  again st
SARS -CoV -2 (including IV RDV ) is prohibited.
Medications will be assessed from screening to the Day  28 Follow -up visit.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 36 13January 20216. STUDY  PROCEDURES
The study  procedures to be conducted for each subject enrolled in the study  are presented in 
tabular form in Appendix 3and described in the text that follows.
The investigator must document any deviation from the protocol procedures and notify  Gilead or 
contract research organization.
6.1. Subject Enrollment and Treatment Assignment
Entry  into screening does not guara ntee enrollment into the study . In order to manage the total 
study enrollment, Gilead, at its sole discretion, may  suspend screening and/or enrollment at any  
site or 
study -wide at any  time. In Part C of the study , study visits may  be performed in -clinic or
at the participant’s home via home health and/or telehealth, virtually  or remotely , as permitted by  
local and institutional regulations.
6.2. Pretreatment Assessments
6.2.1. Study Parts A, B, and C: Screening Visit
Subjects will be screened in-clinic within 2 day sbefore randomization to determine eligibility  
for participation in the study . The following will be performed and documented at s creening:
Obtain written informed consent , orwith a legal representative who can provide informed 
consent
After the informed c onsent the following assessments are performed to determine eligibility  
requirements as specified in the inclusion and exclusion criteria :
Obtain medical history including the following infor mation (eg,date of first sy mptoms, 
overall s ymptoms, exposure so
urce, demographics, baseline characteristics), allergies, and 
medical history
Review concomitant medications
Complete phy sical examination (urogenital/reproductive/anorectal exams will be performed 
only if clinicall y indicated) including vital signs (heart rate, temperature, blood pressure, and 
SpO 2), body  weight, and height
Urine pregnancy  test (females of childbearing potential only )
Childbearing f emale participants who are not postmenopausal (see Appendix 5) who do not 
wish to follow protocol -
defined contraception will need a s erum follicle -stimulating hormone 
(FSH)test(FSH test is required for women who are < 54 years old and have stopped 
menstruating for ≥ 12 months but do not have documentation of ovarian hormonal failure)
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 37 13January 2021Documentation of SARS -CoV -2 infection first confirmed by  PCR (Parts A and B) or b y 
nucleic acid testing or direct antigen testing (Part C) with sample collected ≤ 4days prior to 
randomization
Record an y SAEs and all AEs related to protocol- mandated procedures occurring after 
signing of the consent form
In Stud y Parts A and B, s tudy subjects who qualify  should be immediatel y randomized. 
Randomization and dosing should occur on the same day  if possible.
From the time of obtaining informed consent through the first administration of study  treatment , 
record all SAEs, as well as an y AEs related to protocol -mandated procedures on the AEs
electronic case report form (eCRF). All other unto ward medical occurrences observed during the 
screening period, including exacerbation or changes in medical history are to be considered 
medical history . See Section 7Adverse Events and Toxicity  Management for additional details.
6.2.2. Study Parts A and B: 
Baseline /Day 1 Assessments
The following evaluations are to be completed at the Day  1 visit in-clinic . The investigator must 
have confirmed eligibility  before proceeding with randomization. I f the screening and Day  1 
visits occur on the same day, no procedures need to be repeated. Participants must complete the 
following assessments before being administered st udy treatment , unless otherwise stated :
Complete sy mptom -directed phy sical e xamination including vital signs (heart rate, 
temperature, blood pressure
, SpO2)
Perform 12-lead electrocardiogram ( ECG )
Perform 
FEV 1(predose and 10 minute spostdose )
Repeat of FEV 1should be performed 30minutes postdose if there is > 15% reduction in 
FEV 1at 10 minutes postdose compared with the sa meday predose FEV 1.FEV 1
assessment may  also be performed if there is a clinical concern of bronchospasm
Perform chest x -ray
Comple te daily  adapted FLU -PRO©questionnaire
Safety  laboratory  samples will be collected for the following analy ses:
Hematology
Coagulation
Chemistry
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-553-9020 
Gilead Sciences, Inc. FINAL 
Amendment3 
• Obtain nasopharyn geal and oropharyngea l swabs, and saliva samples for SARS-CoV-2 
quant itative reverse transcr iptase polymerase chain reaction (RT-qPCR ) testing and poss ible 
viral resistance testing 
• --n a PK assessment: end of nebu lization 
I 
I 
• R eview AEs and concom itant medications 
• Inhal ed Remdesivir for Injection fonnu lation administrat ion: 
6.3. Inhal ed Remdesivir for Injection fonnu lation will be administered to participants at the 
site under close superv ision. 
Healthcare profess ionals administering inhaled Remdesivir for Injection fonnu lation 
shou ld have the appropr iate medication available for imm ediate use in case of 
hypersens itivity. The participant shou ld be treated accord ing to the standard of care 
(SOC) for mana gement of hypersens itivity react ion. After dose administrat ion, 
monitorin g shou ld be done as follows: 
Approx imately 30 minut es post dose adm inistrat ion, partici pants shou ld be observed, 
and vital signs shou ld be perfonned prior to discharge 
Study Parts A and B: Daily Study Assessments (Days 2-5) 
The following evaluations are to be completed daily and prior to study treatment administrat ion 
from Days 2-5 in-clin ic, unless otherw ise stated: 
• Comp lete symptom-dir ected physica l examination includ ing vital signs (h eart rate, 
temperature, blood pressure, SpO2) 
• Comp lete daily adapted FLU-PRO © quest io1ma ire 
• Safety laboratory samples (Days 3 and 5) 
CONFI DENT IAL Page 38 13 January 2021 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 39 13January 2021Obtain nasophary ngeal ,orophary ngeal swabs , and saliva samples for SARS -CoV -2 
RT-qPCR testing and possible viral resistance testing
Perform FEV 1(predose and 10 minutes postdose)
Repeat of FEV 1should be performed 30 minutes postdose if there is >
15% reduction in 
FEV 1at 10 minutes postdose compared with the same day  predose FEV 1.FEV 1
assessment may  also be performed if there is a clinical concern of bronchospasm
Sparse plasma PK assessment : predose and end of nebulization (Day 3)
Review AEs and concomitant medications
Inhaled Remdesivir for Injection formulation administration:
Inhaled Remdesivir for Injection formulation will be administered to participants at the 
site under close supervision. Healthcar e professionals administering inhaled Remdesivir 
for Injection formulation should have the appropriate medication available for immediate 
use in case of h ypersensitivity. The participant should be treated according to the SOC
for management of hypersensiti vity reaction. After dose administration, monitoring 
should be done as follows:
Approximately  30 minutes post dose administration, participants should be observed, and 
vital signs should be performed prior to discharge
6.4. Study Parts A and B: 
Follow -UpAssessments (Day s7 and 14)
The following evaluations are to be completed on Days7 and 14 (± 3 day s)in-clinic :
Complete sy mptom -directed phy sical e xamination including vital signs (heart rate, 
temperature, blood pressure, SpO 2)
Complete daily  adapted FLU -PRO©questionnaire
Safety  laboratory  samples
Obtain nasophary
ngeal ,orophary ngeal swabs , and saliva samples for SARS -CoV -2 
RT-qPCR testing and possible viral resistance testing
Single PK 
assessment (Day  7)
Review AEs and concomitant medications
CCII 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 40 13January 20216.5. Study Parts A and B: Day 28 Follow -Up Assessment (± 5 days)
The following evaluations are to be completed on Day  28 and may be completed by  telephone:
Review AEs and concomitant medications
6.6.
Study Part C: Baseline/Day 1, Days 3, 5, and 7Assessments
The investigator must have confirmed eligibility  before proceeding with randomization. If the 
screening and Day  1 visits occur 
on the same day , no procedures need to be repeated. Whenever 
possible, Day 1dosing should occur on the same day  as screening. The following evaluations are 
to be completed atDays 1, 3, 5, and 7. They  may  be completed at home with the assistance of 
home nursing . Participants must complete the following assessments before being administered 
study  treatment, unless otherwise stated:
Complete sy mptom -directed phy sical e xamination including vital signs (heart rate, 
temperature, blood pressure , SpO 2)
Complete daily  adapted FLU -PRO©questionnaire
On Day s 1through 
5, perform FEV 1(predose and 10 minutes postdose)
Repeat of FEV 1should be performed 30 minutes postdose if there is > 15% reduction in 
FEV 1at 10 minutes postdose compared with the same day  predose FEV 1.FEV 1
assessment may  also be performed if there is a clinical concern of bronchospasm
Obtain nasopharyngeal andoropharyngeal swabs, and saliva samples for SARS -CoV -2 
RT-qPCR testing and possible viral resistance testing
PK assessment s
Days
3and 5 : Sparse plasma PK assessment at predose
Day 7: Single an ytime plasma PK assessment
Safety  laboratory samples (Days 1, 3, 5, and 7)
Review AEs and concomitant medications
Remdesivir for Inhalation Solution formulation administration (Day s 1
-5):
Remdesivir for Inhalation Solution formulation may be administered at home to 
participants with in-person or telehealth support
For participants with pre -existing pulmonary  conditions (ie ,chronic obstructive 
pulmonary  disease [ COPD ]or asthma) enrolled in Part C of the study ,prescribed inhalers 
may not be used ≤ 30 minutes prior to Remdesivir for Inhalation Solution formulation 
administration
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 41 13January 2021Healthcare professionals overseeing Remdesivir for Inhalation Solution formulation 
therap y remotely will observe the patient for an y signs of adverse e vent. If any adverse 
event is observed and cannot be managed remotely  appropriate urgent c are measures will 
be implemented. 
■Approximately  30 minutes after dose administration, participants should be observed
remotely prior to telehealth support session concluding
6.7. Study Part C: Day s2 and 4 Assessments
The following evaluations are to be comple ted daily  and prior to study  treatment administration 
onDays 2and 4 . They  may  be completed at home with telehealth support, unless otherwise 
stated:
Complete d aily adapted FLU -PRO©questionnaire
Perform FEV 1(predose and 10 minutes postdose)
Repeat of FEV 1should be performed 30 minutes postdose if there is > 15% reduction in 
FEV 1at 10 minutes postdose compared with the same day  predose FEV 1.FEV 1
assessment may  also be performed if there is a clinical concern of bronchospasm
Review AEs and concomitan t medications
Remdesivir for Inhalation Solution formulation administration:
Remdesivir for Inhalation Solution formulation may be administered at home to 
participants with in-person or telehealth support
For participants with pre -existing pulmonary  condit ions (ie ,COPD or asthma) enrolled in
Part C of the study ,prescribed inhalers may  not be used ≤
30 minutes prior Remdesivir 
for Inhalation Solution formulation administration
Healthcare professionals overseeing Remdesivir for Inhalation Solution formulati on 
therap y remotely will observe thepatient for an y signs of adverse event . If any  adverse 
event is observed and cannot be managed remotely  appropriate urgent care measures will 
be implemented. 
■Approximately  30 minutes after dose administration, participants should be observed
remotely prior to telehealth support session concluding
6.8. Study Part C: Follow- Up Assessments (Days 14 and 28)
The following evaluations are to be completed on Day  14 (± 3 day s) and Day  28 (± 5 day s) and 
may be completed by  telephone:
Complete d aily adapted FLU -PRO©questionnaire (Day  14 onl y)
Review AEs and concomitant medications
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 42 13January 20216.9. Chest X -Ray
In Stud y Parts A and B, a chest x -ray will be performed at Day  1. If screening visit and Day  1 are 
the same day , chest x -ray does not need to be repeated if completed as SOC < 2 day s before 
screening . 
6.10. FEV 1
FEV 1will be performed daily  during treatment day s and will be performed both 
predose and 
10minutes postdose .Repeat FEV 1should be performed at 30 minutes postdose if there is 
> 15% reduction in FEV 1at 10 minutes postdose compared with the sa meday pre-dose FEV 1.
FEV 1assessment may  also be performed if there is a clinical concern of bronchospasm.
Allsubjects with >15% reduction in FEV 1compared with same day  predose FEV1 should be
monitored until FEV 1normalizes.
FEV 1assessments will be performed as per the current American Thoracic Society  
Standardization.
6.11. Clinical Laboratory Assessments
Clinical laboratory  assessments will be performed throughout the stud y as outlined below and in
Appendix 3.
The following clinical laboratory  assessments will be 
performed at screening and anal yzed 
locally  at sites:
Urine pregnancy  test (females of childbearing potential only )
FSH testing (screening only ): females who are < 54 years old and have ceased menstruating 
for ≥ 12 months but do not have documentation of ovarian hormonal failure only and do not 
wish to follow protocol -defined contraception
The following clinical laboratory  assessments will be 
performed at the applicable visits and sent 
to a central laboratory  for anal ysis:
Chemistry : alkaline phosphatase, AST, ALT, gamma -glutam yl transferase , total bilirubin, 
direct and indirect bilirubin, total protein, albumin, lactate deh ydrogenase, creatine 
phosphokinase , bicarbonate, blood urea nitrogen , calcium, chloride, creatinine, glucose, 
lipase, magnesium, phosphorus, potassium, sodium, uric acid 
Hematology : hematocrit, hemoglobin, pla telet count, red blood cell count, white blood cell
count with differential (absolute and percentage), including l ymphocy tes, monocy tes, 
neutrophils, eosinophils, basophils, 
andmean corpuscular volume
Coagulation panel: prothrombin time, partial thrombop lastin time ,and international 
normalized ratio
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 43 13January 2021Virology  assessments: nasophary ngeal and orophary ngeal swab samples and saliva samples 
will be used to assess SARS- CoV -2 viral load by  RT-qPCR. Once viral load testing is 
complete, the remnant samples may  be used to evaluate the emergence of viral resistance by  
SARS -CoV -2 sequencing and/or phenot ypic testing
Estimated glomerular filtration rate will be determined according to:
Cockcroft -Gault formula for creatinine clearance for participants ≥ 18 y ears of age
Creatinine clearance will be estimated based on 
screening body  weight
Men: (140 age in years) ×(wt in kg)  creatinine clearance ( CLcr)(mL/min)
72 ×(serum creatinine in mg/dL)
Women: (140 age in years) ×(wt in kg) × 0.85  CLcr (mL/min)
72 × (serum creatinine in mg/dL)
6.12. Pharmacokinetic Assessments
Sparse plasma PK
assessments will be conducted in all participants in Part sA, B ,and C . In 
Study  Parts A and B, s parse plasma PK samples will be collected at Day  1 (end of nebulization, 
) and Day  3 (predose and end of nebulization). In 
Study  Part C, sparse plasma PK samples will be collected at Days 3and 5 (predose) and a single 
anytime PK sample will be collected on Day  7.
Up to 6 participants/group in Part A and Part B will have intensive PK assessments. I ntensive PK
samples 
will be collected at Day  1 and an additional collection, either at Day  3 or Day  5, at the 
following time points relative to the end of nebulization: 0 (pre dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 
and 24 hours post end of nebulization. An additional single PK sample will be collected on 
Day 7 visit for subjects who participate in the intensive PK assessments.
6.13. Assessments for Early Discontinuation from Study
If a participant discontinu es study  dosing (for example, as a result of an AE), every  attempt 
should be made to keep the participant in the study  and continue to perform the required 
study -related follow- up and procedures (see Section 6.13.1, Criteria for Discontinuation of Study  
Treatment). If this is not possible or acceptable to the participant or investigator, the participant 
may be withdrawn from the study .
6.13.1.
Criteria for Discontinuation of Study Treatment
Study  treatment may be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree. Following resolution of intercurrent illness , the subject 
may resume study  dosing if supported by both investigator and Gilead medical monitor
CCI
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-553-9020 
Gilead Sciences, Inc. FINAL 
Amendment3 
• Unacc eptab le toxicity, or toxic ity that, in the judgment of the invest igator, comprom ises the 
ability to continue study-spec ific proce dures or is cons idered to not be in the subject's best 
interest 
• Lack of efficacy 
• Subject request to discont inue for any reason 
• Subject noncomp liance 
• Pregnancy durin g the study; refer to Appendix 5 
• Discont inuation of the study at the request of Gilead, a regu latory agency, or an institutional 
review board (IRB) or indepen dent ethics c01mn ittee (IEC) 
• Any SAE or~ Grade 3 AE suspecte d to be related to RDY 
• FEY I decline of> 15% at 30 minut es postdose compare d with same d ay predose FEY 1 
• M eeting toxic ity mana gement criteria necess itating discont inuation, refer to Section 7.7. 
6.14. End of Study 
The end of the study w ill occur at the last participant's last observat ion ( or visit). 
6.15. Poststudy Care 
The long-tenn care of the participant will rema in the respons ibility of their primary treat ing 
physic ian. Remdesivir is being supp lied wi th curat ive intent. There is no prov ision for poststu dy 
availability. 
6.16. Sample Storage 
The store d biol ogical samples may be used by Gilead or its research partner for future testing to 
provi de additional data to answer questions that relate to the main study. At the end of this study, 
these samples may be retained in storage by Gilead for a period up to 15 years . If subjects 
provi de additional spec ific consent, residual PK samples may be destroye d no later than 15 years 
after the end of the study or per country requirements . 
CONFI DENT IAL Page 44 13 January 2021 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 45 13January 20217. ADVERSE EVENTS AND T OXICITY  MANAGEMENT
7.1. Definition sof Adverse Events and Serious Adverse Events
7.1.1. Adverse Events
An AE is any untoward medical occurrence in a clinical study subject administered a study 
treatment , which does not necessaril y have a causal relationship with the treatment. An AE can 
therefore be an y unfavorable and/or unintended sign, s ymptom, or disease temporally  associated 
with the use of a stud y treatment , whether or not the AE is considered re lated to t he study  
treatment . Adverse event s may  also include pre treatment or posttreatment complications that 
occur as a result of protocol -specified procedures or special situations (Section 7.1.3).
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy ,tooth extraction, and transfusion. 
T
he condition that ledto the procedure may  be an AE and must be reported
Preexisting diseases ,conditions ,or laboratory  abnormalities present or detected before the 
screening visit that donot worsen
Situations where an untoward medical occurrence has not occurred ( eg,hospitalization for 
elective surgery , social and/or convenience admissions)
Overdo se without clinical sequelae (Section 7.1.3)
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the informed consent for m (ICF
)is signed and not related to a protocol -associated 
procedure is not an AE but rather considered to be preexisting and should be documented as 
medical history .
Preexisting events that increase in severity  or change in nature after study  treatment initiation or 
during or as a consequence of participation in the clinical study  will also be considered AEs.
7.1.2. Serious Adverse Events
A
nSAE is defined as an event that, at an y dose, results in the following:
Death
A life-threatening situation (Note: The ter m “life -threatening” in the definition of “serious” 
refers to an event in which the subject was at risk of death at the time of the event; it does not 
refer to an event that hy pothetically  might have caused death if it were more severe.)
In-patient hospitalization or prolongation of existing hospitalization
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 46 13January 2021Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: S uch events may  not be immediately  
life-threatening or result in death or hospitalization but may  jeopardize the subject or may  
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of m edically  important e vents include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; anddevelopment of drug dependency  or 
drug abuse .
7.1.3. Study Treatments and Gilead Concomitant Therapy Special Situations 
Reports
Special situation reports (SSRs) 
include all reports of medication error, abuse, misuse, overdose, 
occupational exposure, drug interactions, exposure via breastfeeding, unexpected benefit, 
transmission of infectious agents via the product, counterfeit of falsified medicine, and 
pregnancy  regardless of an associated AE.
Medication error is an y unintentional error in the prescribing, dispensing , preparation for 
administration or administration of a study  treatment while the medication is in the control of a
health care professional , patient, or consumer. Medication errors may  be classified as a 
medication error without an AE, which includes situations of missed dose, medication error w ith 
an AE, intercepted medication error, or potential medication error.
Abuse is defined as persistent or sporadic intentional excessive use of a study  treatment by a 
subject.
Misuse 
is defined as an y intentional and inappropriate useof a stud y treatment that is not in 
accordance with the protocol instructions or the local prescribing information .
An overdose is defined as an accidental or intentional administration of a quantity  of a stud y 
treatment given per administration or cumulatively which is above the maximum recommended 
dose as per protocol or in the product label ing(as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy, except in cases in which the investigator 
has reason to suspect that the subject has taken the additional dose(s).
Occupational exposure is define d as exposure to a study  treatment as a result of one’s 
professional or nonprofessional occupation.
Drug interaction is defined as an y drug/drug, drug/food, or drug/device interaction.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 47 13January 2021Unexpected benefit is defined as an unintended therapeutic effect where the results are judged to 
be desirable and beneficial.
Transmission of infectious agents is defined as any  suspected transmission of an infected agent 
through a Gilead stud y treatment .
Counterfeit or falsified medicine: An y study treatment with a false representation of (a) its 
identity , (b) its source, or (c) its history .
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for fina l review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Treatments and Procedures
The investigator or qualified subinvestigator is responsible for assessing t he relationship to study  
treatment using cli nical judgment and the following considerations:
No: Evidence exists that the AEhas an etiology  other than the study  treatment . For SAEs, an 
alternative causality
 must be provided (eg, pre existing condition, underl ying disease, 
intercurrent illness, or co ncomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by the study  
treatment .
It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of AE reporting.
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the AE has an etiology  other than the study  procedure.
Yes: The AEoccurred as a result of protocol procedures (eg,venipuncture ).
7.2.2. Assessment of Severity
The severit y of AEs will be graded using the Division of AIDS ( DAIDS) Table for Grading the 
Severity  of Adult and Pediatric Adverse Events, Version 2.1 dated July  2017. For each episode, 
the highest grade attained should be reported as defined in the grading scale. The DAIDS scale is 
available at the following location:
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 48 13January 20217.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events
7.3.1. Requirements for Collection Prior to Study Treatment Initiation
After informed consent, but prior to initiation of study  treatment , the following t ypes of events 
must be reported on th e applicable eCRFs: all SAEs and AEs related to protocol -mandated 
procedures.
7.3.2. Adverse Events
Following initiation of study  treatment , collect a ll AEs, regardless of cause or relationship, 
including the protocol -required posttreatment follow -up period must be reported on the eCRFs as 
instructed.
All AEs and clinicall
y significant laboratory abnormalities should be followed until resolution or 
until the AE is stable, if possible. Gilead may request that certain AEs be followed bey ond the 
protocol -defined follow- up period.
7.3.3. Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur after the subject first consents to 
participate in the stud y (ie, signing the ICF) and throughout the duration of the study , including 
the posttreatment follow -upvisit, must be reported onthe applicable eCRFs and Gilead GLPS 
(formerl y PVE )as instructed below in this section . This also includes an y SAEs resulting from 
protocol -associated procedures performed after the ICFis signed.
Any SAEs and deaths that occu r after the posttreatment follow -up visit but within 30 days of the 
last dose of study  treatment, regardless of causality, should also be reported.
Investigators are not obligated to activel y seek SAEs after 
the protocol -defined follow -up perio d;
however, if the investigator learns of any  SAEs that occur after the protocol -defined follow - up 
period has concluded and the event is deemed relevant to the use of study  treatment, the 
investigator should promptly  document and report the event to Gilead GLPS .
Instructions for reporting SAEs are described in Section 7.4.1.
7.3.4. Study Treatment Special Situations Reports
All study  treatment SSRs that occur from study  treatment i nitiation and throughout the duration 
of the study , including the posttreatment follow -up visit, must be reported to Gilead GLPS 
(Section 7.4.2). Adve rse events and SAEs resulting from SSRs must be reported in acc ordance to 
the AE and SAE reporting guidance ( Section 7.3).
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 49 13January 20217.3.5. Concomitant Therapy Reports
7.3.5.1. Gilead Concomitant Therapy  Special Situations Report
Special situation reports involving a Gilead concomitant therapy (not considered stud y 
treatment ), that occur safter the subject first consents to participate in the study  (ie, signing the 
inform ed consent) and throughout the duration of the study , including the posttreatment 
follow -upvisit, must be reported to Gilead GLPSutilizing the paper SSR (Section 7.4.2.1).
7.3.5.2. Non-Gilead Concomitant Therap y Report
Special situations involving non -
Gilead concomitant medications does not need to be reported on 
the SSR form; however, for special situations that result in AEs due to a non- Gilead concomitant 
medication, the AE should be reported on the AE form.
Anyinappropriate use of concomitant medications prohibited by this protocol should not be 
reported as “misuse,” but may be more appropriately documented as a protocol deviation.
All clinical sequelae in relation to these SSRs will be reported as AEs or SAEs at the same time 
using the AE eCRF and/or the SAE report form. Deta ilsofthesymptoms and signs, clinical 
management, and outcome will be reported, when available.
7.4. Reporting Process for Serious Adverse Events and Special Situation Reports
7.4.1. Serious Adverse Event Reporting Process
For fatal or life -threatening events, copies of hospital case reports, autops y reports, and other 
documents are alsoto be transmitted by  email or fax when requested and applic able. 
Transmission of such documents should occur without personal subject identification, 
maintaining the tra ceability  of a document to the subject identifiers.
Additional information may  be requested t o ensure the timely  completion of accurate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s eCRF and the SAE narrative section of the Safet y Report 
Form eCRF .
7.4.1.1. Electronic Serious Adverse Event Reporting Process
Site pe rsonnel will record all SAE data on the applicable eCRFs and from there transmit the 
SAE information to Gilead GLPS within 24 hours of the investigator’s knowledge of the 
event from ICF signature throughout the duration of the stud y, including the 
protocol -required posttreatment follow- up period.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 50 13January 2021If it is not possible to record and transmit the SAE information electronically , record the SAE 
on the paper SAE reporting form and transmit within 24 hours:
Gilead GLPS Gilead GLPS Email:  
or
Fax: 
If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary . If the database is not locked, an y SAE reported via paper must be 
transcribed as soon as possible on the applicab le eCRFs and transmitted to GLPS.
7.4.2. Special Situations Reporting Process
7.4.2.1. Paper Special Situations Reporting Process for Study  Treatment
All SSRs will be recorded on the special situations report form and transmitted by emailing 
or faxing the report form within 24 hours of the investigator’s knowledge of the event to the 
attention of Gilead GLPS from study  treatment initiation throughout th e duration of the 
study, including the protocol required post treatment follo w
-up period.
Gilead GLPS Gilead GLPS Email  
or
Fax: 
7.4.2.2. Reporting Process for Gilead Concomitant Medications
Special situations that involve Gi lead concomitant medications that are not considered stud y 
treatment must be reported within 24 hours of the investigator’s knowledge of the event to 
Gilead GLPS utilizing the paper special situations report form to:
Gilead GLPS Gilead GLPS Email  
or
Fax: 
Any inappropriate use of concomitant medications prohibited by  this protocol should not be 
reported as “misuse,” but may  be more appropriately  documented as a protocol deviation.
Special situations involving non-Gilead concomitant medications donot need to be reported
on the SSR form; however, special situations that result in AEs due to a non -Gilead 
concomitant medication, must be reported as an AE .
PPD
PPD
PPD
PPD
PPD
PPD
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 51 13January 20217.4.2.3. Pregnancy  Reporting Process
Theinvestigator should report pregnancies in female study  subjects and/or female partners of 
male subjects that are identified after initiation of study  treatment and throughout the stud y, 
including the post study  treatment follow -up period, to Gilead GLPS using the pregnancy  
report form within 24 hours of becoming aware of the pregnancy . Contact details for 
transmitting the pregnancy report form are as follows:
Gilead 
GLPS Gilead GLPS 
Email:  
or
Fax: 
The pregnancy  itself is not considered an AE ,nor is an induced elective abortion to terminate 
a pregnancy  without medical reasons.
All other premat ure terminations of pregnancy  (eg, a spontaneous abortion, an induced 
therapeutic abortion due to complications or other medic al reasons ) must be reported with in 
24hours as an SAE, as described in Section 7.4.1. The underl ying medical reason for this 
procedure should be recorded as the AEterm.
A spontaneous abortion is alway s considered to be an SAE and w ill be reported as described 
in Section 7.4.1. Furthermore, an y SAE occurring as an adverse pregnancy outcome post 
study  must be reported to the Gilead 
GLPS .
The subject should receive appropriate monitoring an d care until the conclusion of the 
pregnancy . The outcome of the pregnancy /partner pregnancy should be reported to Gilead 
GLPS using the pregnancy  outcome report form. If the end of the pregnancy /partner 
pregnancy occurs after the study  has been completed, the outcome should be reported 
directly  to Gilead GLPS . Gilead GLPS contact information is as follows: 
email  and f ax: .
Refer to Appendix 5for Pregnancy  Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements.
7.5. Gilead Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US F DACode of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, Gilead may  berequired to expedite to 
worldwide regulatory  agencies reports of SAEs which may  be in the form of line listings, serious 
adverse drug reactions
,or SUSARs. In accordance with the EU Clinical Trials Directive 
(2001/20/EC), Gilead or a specified designee will notify  worldwide regulatory  agencies and the 
relevant IECin concerned Member States of applicable SUSARs as outlined in current 
regulations.
PPD
PPD
PPD
PPD
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 52 13January 2021Assessment of e xpectedness forSAEs will be determined by  Gilead using reference safety  
information specified in the IBor relevant local label as applicable.
All investigators will receive a safet y letter notify ing them of relevant SUSAR reports associated 
with any  study  treatment . The investigator should notify  the IRB or IEC of SUSAR reports as 
soon as is practical, where this is required b y local regulatory agencies, and in accordance with 
the local institutional policy .
7.6. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not to be recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , urinaly sis) that require 
medical or surgical intervention or lead to study  treatment interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition,
laboratory  or other abnormal assessments (eg, electrocardiogram, x
-rays, vital signs) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.1 and 7.1.2. If the laboratory  
abnormality  is part of a syndrome, record the s yndrome or diagnosis (eg, anemia), not the 
laboratory  result (ie, decreased hemoglobin).
Severity  should be recorded and graded according to the DAIDS scale, Version 2.1.For AEs 
associated with laboratory  abnormalities, the event sh ould be graded on the basis of the clinical 
severit y in the context of the underl ying conditions; this may  or may not be in agreement with 
the grading of the laboratory  abnormalit y
.
All AEs, SAEs, and clinically  significant laboratory  abnormalities will be followed until 
resolution or until stability  of the abnormalit y is demonstrated.
7.7. Toxicity Management
Nebulized RDV will be administered to participants under close supervision.
Inhaled 
Remdesivir for Injection formulation will be administered to particip ants at the clinical 
site (Parts A and B) . Healthcare professionals administering inhaled Remdesivir for Injection 
formulation should have the appropriate medication available for immediate use in case of 
hypersensitivity . The participant should be treated according to the SOC for management of 
hypersensitivity  reaction. After dose administration, monitoring should be done as foll ows:
Approximately  30 minutes after dose administration, participants should be observed, and 
vital signs should be performed prior to discharge (Parts A and B only )
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 53 13January 2021Remdesivir for Inhalation Solution formulation may be administered to participants in the
participant’s home with in-person or telehealth support (Part C only ). Healthcare professionals 
overseeing Remdesivir for Inhalation Solution formulation therapy  remotely  will observe the 
patient for an y signs of adverse event. If an y adverse event is obs erved and cannot be managed 
remotely ,appropriate urgent care measures will be implemented. 
Approximately  30 minutes after dose administration, participants should be observed
remotely prior to telehealth support session concluding
For participants with p re-existing pulmonary  conditions (ie ,COPD or asthma) enrolled in Part C 
of the study ,prescribed inhalers may  not be used ≤ 30 minutes prior to Remdesivir for Inhalation 
Solution formulation administration
.
The participant should be treated according to the SOC for management of hy persensitivity  or 
bronchospasm according to site or home health protocol. The medical monitor should be notified 
prior to study  treatment discontinuation when medically  feasible. St udy treatment dosing in an 
individual participant will be placed on hold and may be permanently  discontinued, following 
review of all available clinical data by the Medical Monitor and discussion with the investigator, 
in the following conditions:
Developm ent of ALT levels ≥ 5 × ULN
Development of ALT levels ≥ 3 × ULN and bilirubin ≥ 2 × ULN
Acute anaph ylactic reaction to RDV
Estimated creatinine clearance < 30 mL/min based on the Cockcroft -Gault formula
Any SAEs and Grade 3 and 4 abnormal laboratory results assessed as related to study  
treatment
For clinical queries, please contact the medical monitor. Study  treatment dosing may  be resumed 
if it was 
held due to laboratory abnormalit y and is now within acc eptable range, if the 
abnormality  was not attributed to study  treatment .
Please refer to Appendix 4for further details on the management of clinical and laboratory  AEs.
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-553-9020 
Gilead Sciences, Inc. 
8. 
8.1. 
8.1.1. STATISTICAL CONSIDERATIONS 
Analysis Objectives and Endpoints 
Analysis Objectives 
The primary objective of this study is: FINAL 
Amendment3 
• To ch aracter ize the impact of inhaled RDV on SARS-CoV-2 viral load in partici pants with 
early stage COV ID-19 
The secon dary objectives of this study are: 
• To evaluate the safety and tolerability of inhaled Remd esivir for Injection fonn ulation in 
partici pants with early stage COV ID-19 
• To evaluate the PK of inhaled Remd esivir for Inject ion fonnulation and its metabo lites in 
partici pants with early stage COV ID-19 in P arts A and B 
• To character ize and evaluate disease progress ion from baseline 
• To ch aracter ize the efficacy, safety, and tolerability of Remd esivir for Inhalation Solution 
fonnulation ad mini stere d with a mouthpiece in Part C of the study 
I 
I 
8.1.2. Primary Endpoint 
• Time-we ighted average change in SARS-CoV-2 viral load which is de fined as AUC of viral 
load change divided by time betwee n base line through Day 7 
8.1.3. Secondary Endpoint 
The secon dary endpoints of this study are: 
• P roport ion of participants with TEA Es and laboratory abnon n alities 
• P roportion of partic ipants with TEA Es leading to study treatment di scont inuation 
• Com posite of all-cause MA Vs (medi cal visi ts atten ded in perso n by the participant and a 
health care profess ional) or death by Day 28 
CONFI DENT IAL Page 54 13 January 2021 
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-553-9020 
Gilead Sciences, Inc. FINAL 
Amendment3 
• Composite of COV ID-19 related MA Vs (medica l visi ts attended in person by the participant 
and a health care profess ional) or death by Day 28 
• Proportion of participants hospitalized by Day 28 
• Character ization of the plasma concentrat ions of inhaled RDV and its metabo lites includ ing 
AUCo 24h, AUC1as1, CLss !F, t112, V vF, Cmax, Tmax, C1as1, T1as1, AUC1au, ')....L., and C1au (Parts A and B 
only) 
• Change in SARS-CoV-2 viral load from base line to Day 5 
• Change in SARS-CoV-2 viral load from base line to Day 7 
• Change in SARS-CoV-2 viral load from base line to Day 14 (Parts A and B only) 
• Time to negat ive SARS-CoV-2 PCR 
• Time to alleviation (mild or absent) of base line COVID-19 symptom s as reported on the 
COVID-19 adapted FLU-PRO © questionnaire -I 
I 
I 
I 
I 
I 
8.2. 
8.2.1. Planned Analyses 
Interim Analysis 
Prior to the final analysis, interim analyses may be conducted and the analyses may be submitted 
to regu latory agencies to seek guidance for the overa ll clinical deve lopment program . 
CONFI DENT IAL Page 55 13 January 2021 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 56 13January 20218.2.2. Final Analysis
The unblinded final analy sis will be performed at the end of stud y,after all subjects have 
completed the study , outstanding data queries have been resolved or adjudicated as unresolvable, 
and the data have been cleaned and finalized.
8.3. Analysis Conventions
8.3.1. Analysis Sets
8.3.1.1. Efficacy
The primary  anal ysis set for efficacy  anal ysis isdefined as the Full Anal ysis Set, which will 
include all participants who (1) are randomized into the study  and (2) have received at least 
1dose of study  treatme nt. Participants will be grouped according to the treatment to which they  
were randomized .
8.3.1.2. Safety
The primary  anal ysis set for safety anal yses isdefined as Safet y Anal ysis Set, which will include 
all participants who (1) are randomized into the study  and (2) have received at least 1 dose of 
study  treatment. Participants will be grouped according to the treatment which they  received.
8.3.1.3. Pharmacokinetics
Each PK Anal ysis Set will include all randomized subjects who received at least 1dose of study  
treatment and had at least 1 nonmissing PKconcentration datumreported b y the PK laboratory  
for each respective anal yte.
8.3.2. Data Handling Conventions
Natural logarithm transformation for PK parameters will be applied for PK anal ysis.
For summary  statistics, PK concentration values below the limit of quantitation will be treated as 
zero at predose and one -half of the lower limit of quantitation (LLOQ) for postdose time points .
Laboratory  data that are continuous in nature but are less than the LLOQ or above the upper limit 
of quantitation, will be imputed to the value of the lower or upper limit plus or minus 
1significant digit, respectively  (e.g., if the result of a continuous laboratory test is < 20, a value 
of 19 will be assigned).
Missing data can have an impact upon the interpretation of the trial data. In general, values for 
missing data will not be imputed. However, a missing pretreatment laboratory  result would be 
treated as normal ( i.e.
, no toxicity  grade) for the laboratory  abnormality  summary .
All available data for participants that do not complete the study  will be included in data listings.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 57 13January 20218.4. Demographic and Baseline Characteristics Analysis
Demographic and baseline measurements will be su mmarized using standard descriptive 
methods.
Demographic summaries will include sex, race/ethnicity ,and age.
8.5. Efficacy Analysis
8.5.1. Primary Analysis
SARS -CoV -2 viral load will be summarized by  treatment using descriptive statistics in Part A 
and Part B . For 
Part C, time weighted average change in SARS -CoV -2 viral load will be 
compared between the RDV and placebo group susing analysis of covariance with baseline viral 
load included in the model as a covariate .
8.5.2. Secondary Analyses
The proportion of participants all- cause MAV (medical visits attended i n person b y the 
participant and a health care professional) or death byDay 28 will be estimated using 
Kaplan -Meiermethods by treatment group in Part C . The proportion of participants COVID - 19 
related MAVs or death by Day  28 will be estimated using Kaplan -Meier methods by  treatment 
group in Part C. The p roportion of hospitalization by  Day 28will be summarized by  treatment 
group. Kaplan Meier product limit method will be used to estimate time to negative 
SARS -CoV -2 PCR and time to alleviation (mild or absent) of baseline COVID -19 s ymptoms by 
treatment group.
8.6. Safety Analysis
All safet y data collected on or after the randomization date through Day 28will be summarized 
by treatment group ( according to the study  treatment received) . Data for the pretreatment will be 
included in data listings.
8.6.1. Extent of Exposure
A subject’s extent of exposure to study  treatment data will be generated from the study  treatment
administration data. Exposure data will be summarized by  treatment group.
8.6.2. Adverse Events
Clinical and laboratory  AEs will be coded using the Medical Dictionary  for Regulatory  
Activities (MedDRA). Sy stem organ c lass, hig h-level group term, high-level term, preferred 
term(PT), and lower -
level term will be attached to the c linical database.
Events will be summarized on the basis of the date of onset for the event. A TEAE will be 
defined as an y AEthat begin son or 
after the date of first dose of study  treatment up to the date 
of last dose of study  treatment plus 30 day s .
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 58 13January 2021Summaries (number and percentage of subjects) of TEAEs (by system organ classand PT) will 
be provided b y treatment group.
8.6.3. Laboratory Evaluations
Selected laboratory  data will be summarized using onl y observed data. Data and change from 
baseline at all scheduled time points will be summarized.
Graded laboratory  abnormalities will be defined using the grading scheme in DAIDS Table for 
Grading the Severity  of Adult and Pediatric Adverse Events, Version 2.1 dated July 2017.
Incidence of treatment -emergent l aboratory  abnormalities, defined as values that increase at least 
1 toxicity  grade from baseline at an y time post baseline up to the end date of the study, will be 
summarized by  treatment group. If baseline data are missing, then an y graded abnormality  (ie, at 
least a Grade 1) will be considered treatment-emergent.
Laboratory  abnormalities that occur before the first dose of study  treatment or after the subject 
has been discontinued from treatment for more than 30 days will be included in a data listing.
8.7. Adjustment s for Multiplicity
No adjustment s
for multiple comparison are planned.
8.8. Pharmacokinetic Analysis
For Part sA and B, plasma concentrations and PK parameters (if applicable) for inhaled RDV 
and its metabolites will be listed and summarized using descriptive statistics by  treatment group 
(including mean, geometric mean, median, minimum, maximum ,and sample size). 
Concentrations of inhaled RDV and its metabolites in plasma over time will be summarized. For 
Part C, plasma concentration of GS-441524 will be listed and summarized using descriptive 
statistics by  nominal time.
8.9. Sample Size
The sample size in this study  is determined based on practical considerations and past experience 
with similar ty pes of studies. No sample size /power calculation was per formed. A sample size up 
toapproximately  152 participants ( 72participants for Part A and Part B ; 80 participants for 
PartC) should provide a suitable assessment of the descriptive efficacy ,and safet y profile in this 
population.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 59 13January 20219. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study is conducted in accordance with International Co uncil
on Harmoni sation (of Technical Requirements for Registration of Pharmaceuticals for Human 
Use) (ICH)E6(R2)addendum to its guideline for GCPandapplicable laws and regulations.
9.1.2. Financial Disclosure
The investig ator and subinvestigators will provide prompt and accurate documentation of their 
financial interest or arrangements with Gilead, or proprietary  interests in the investigational drug 
during the course of a clinical study . This documentation must be provided prior to the 
investigator’s (and an y subinvestigator’s) participation in the study . The investigator and 
subinvestigator agree to notify  Gilead of any change in reportable interests during the stud y and 
for 1 year following completion of the study. Study completion is defined as the date when the 
last subject completes the protocol- defined activities.
9.1.3. Institutional Review Board /Independent Ethics Co mmittee Review and 
Approval
The investigator (or Gilead as appropriate according to local regulations) will submit this 
protocol, ICF, and any  accompan ying material to be provided to the subject (such as 
advertisements, subject information sheets, or descriptions of the study  used to obtain informed 
consent) to an IRB/IEC . The investigator will not begin any  study  subject activities unt il 
approval from the IRB/IEC has been documented and provided as a letter to the investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/IE Cany modifications made to the protocol or any accompan ying material to be 
provided to the subject after initial IRB/IE C approval, with the exception of those necessary  to 
reduce immediate risk to study  participant s.
9.1.4. Informed Consent
The investigator is res
ponsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  before undertaking any  study -related procedures. The investigat or 
must use the most current IRB-or IEC-approved consent form for documenting written informed 
consent. Each informed consent (or assent as applicable) will be appropriately  signed and dated 
by the subject or the subject’s legall y authorized representativ e and the person conducting the 
consent discussion, and also by  an impartial witness (if required b y IRB or IECorlocal 
requirements ).
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-553-9020 
Gilead Sciences, Inc. 
9.1.5. Confidentiality FINAL 
Amendment3 
The invest igator must assure that subjects' anonym ity will be strictly maintain ed and that their 
identities are protecte d from unauthor ized parties. Only an identification code and any other 
unique identifier(s) as allowed by local law (such as year of birth) will be recor ded on any fonn 
or biological sample submitted to Gilead, IRB or IEC or laboratory . Laboratory spec imens must 
be labeled in such a way as to protect subject identity while allowing the results to be recor ded to 
the proper subject. Refer to spec ific laboratory instruct ions or in accor dance with local 
regulations. NOTE: The investigator must keep a scree ning log with details for all subjects 
scree ned and enro lled in the study, in accor dance with the site proce dures and regulations. 
Subject data will be processe d in accor dance with all applicable regu lations. 
The invest igator agrees that all infonnation received from Gilead, including but not limited to the 
IB, this protoco l, eCRF, the study treatment, and any other study infonnation, rema in the sole 
and exclusive property of Gilead during the conduct of the study and thereafter. This infonnat ion 
is not to be disclosed to any third party ( except emplo yees or agents directly involved in the 
conduct of the study or as required by law) without prior written consent from Gilead. The 
investigator further agrees to take all reasonable precautions to prevent the dis closure by any 
employ ee or agent of the study si te to any third party or otherw ise into the public domain. 
9.1.6. Study Files and Retention of Records 
The invest igator must maintain adeq uate and accurate recor ds to enab le the conduct of the study 
to be fully docmnente d and the study data to be subse quently verified. These docmnents should 
be classified into at least the following 2 categor ies: (1) investigator's study file, and (2) subject 
clinical source documents . 
The invest igator's study file will conta in the protoco l/amendm ents, paper or electro nic 
comp leted subject case report fonns (CRFs), IRB or IEC and goven unental approva l with 
correspon dence, infonne d consent, drug records, staff curriculmn vitae and author ization fonns, 
and other appropr iate documents and correspon dence . 
CON FIDENT IAL Page 60 13 January 2021 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 61 13January 2021The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification
Documentation that subject meets eligibility  criteria, ie, medical history , phy sical 
examination, and confirmation of diagnosis (to support inclusion and exclusion criteria)
Documentation of the reason(s) a consented subject is not enrolled
Participation in study  (including study  number)
Study  discussed and date of informed consen t
Dates of all visits
Documentation that protocol -specific procedures were performed
Results 
of efficacy  parameters, as required b y the protocol
Start and end date (including dose regimen) of study  treatment , including dates of dispensing 
and return
Record of all 
AEs and other safety  parameters (start and end date, and including causality  
and severit y), and documentation that adequate medical care has been provided for an y AE
Concomitant medication (including start and end date, dose if relevant; dose chang es)
Date of study  completion and reason for ED , if it occurs
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (ie, the US , Europe, or Japan) and until there are no pending or planned marketing 
applications in an I CH region; or, if no application is filed or if the application is not approved 
for such indication, until 2 years after the investigation is discontinued and regulatory  authorities 
have been notified. Investigators may  be required to retain documents longer if specified by  
regulatory
 requirements, by  local regulations, or by  an agreement with Gilead. The investigator 
must notify  Gilead before d estro ying any clinical study records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study  site for any  or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securel y awa y from the site so that they  can be returned sealed to the investigator 
in case of a n inspection . When sourc e documents are required for the continued care of the 
subject, appropriate copies should be made for storage away  from the site.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 62 13January 20219.1.7. Case Report Forms
For each subject consented, an eCRF casebook will be completed b y an authorized study staff 
member whose tra ining for this function is completed in the EDC system. The eCRF casebook 
will only  capture the data required per the protocol schedule of events and procedures. The 
Inclusion/Exclusion Criteria and Enrollment eCRFs should be completed only  after all data 
related to eligibility  have been received. Data entry  should be performed in accordance with the 
CRF Completion Guidelines provided b y the Sponsor. Subsequent to data entry , a stud y monitor 
will perform source data verification (SDV) within the EDC sy stem. System -generated or 
manual queries will be issued in the EDC sy stem as data discrepancies are identified by  the 
monitor or Gilead staff, who routinely review the data for completeness, correctness, and 
consistency .The site investigator or site coordinator or other designee is responsible for 
responding to the queries in a timely  manner, within the sy stem, either b y confirming the data as 
correct or updating the original entry  and providing the reason for the update (e.g. data entry  
error). Original entries as well as an y changes to data fields will be stored in the audit trail of the 
system. At a minimum, prior to any  interim time points or database lock (as instructed by  
Gilead), the investigator will use his/her log in credentials to confirm that the for ms have been 
reviewed, and that the entries accurately reflect the information in the source documents. At the 
conclusion of the study , Gilead will provide the site investigator with a read -only archive copy  of 
the data entered b y that site. This archive must be stored in accordance with the records retention 
requirements outlined in Section 9.1.6.
9.1.8.
Investigator Inspections
The investigator will make available all source documents and other records for this study to 
Gilead’s appointed stud y monitors , to IRBs/IECs, or to regulatory  authority or health authorit y 
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immed iate risk to study subjects, may  be 
made only  by Gilead. The investigator must submit a ll protocol modifications to the I RB or IEC 
in accordance with local requirements and receive documented IRB or IEC approval before 
modifications can be implemented.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 63 13January 20219.2.2. Study Report and Publications
A clinical study  report will be prepared and provided to the regulatory  agency (ies). Gilead will 
ensure that the report meets the standards set out in the I CH Guideline for Structure and Content 
of Clinical Study  Reports (I CHE3). Note that an abbreviated report may  be prepared in certain 
cases.
Investigators in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
The results of the study  in their entiret y have been publicly disclosed b y or with the consent of 
Gilead in an abstract, manuscript, or presentation form or the stud y has been completed at all 
study  sites for at least 2 years.
The investigator will submit to Gilead any  proposed publication or presentation along with the 
respective scientific journal or presentation forum at least 30 day s before submission of the 
publication or presentation.
No such communication, presentation, or publication will includ
e Gilead’s confiden tial 
information ( see Section 9.1.5).
The investigator will comply  with Gilead’s request to delete references to its confidential 
information (othe r than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1.
Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, eg, attendance at I nvestigator Meetings. If required under the applicable statutory  and 
regulatory  requirements, Gilead will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical study payments, meal, 
travel expenses or reimbursements, consulting fees, and an y other transfer of value.
9.3.2. Access to Information for Monitoring
The monitor is responsible for routine review of the eCRF at regular intervals throughout the 
study  to verify  adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y subject records neede d to 
verify  the entries i n the eCRF . The investigator agrees to cooperate with the monitor to ensure 
that any  problems detected through an y type of monitoring (central, on site) are resolved.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 64 13January 20219.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of Gilead may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the Gilead medical monitor immediat ely. The investigator agrees to 
provide to representatives of a regulatory  agency  or Gilead access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both Gilead and the investigator reserve th e right to terminate the study  at any  time. Should this 
be necessary , both parties will arrange discontinuation procedures and notify  the subjects, 
appropriate regulatory  authority (ies), IRBs, or IECs. I n terminating the study, Gilead and the 
investigator will assure that adequate consideration is given to the protection of the subjects’ 
interests.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 65 13January 202110. REFERENCES
Assiri A, Al -Tawfiq JA, Al -Rabeeah AA, Al -Rabiah FA, Al -Hajjar S, Al -Barrak A, et al. 
Epidemiological, Demographic, and Clinical Cha racteristics of 47 Cases of 
Middle East Respiratory  Syndrome Coronavirus Disease From Saudi Arabia: A 
Descriptive Study . Lancet I nfect Dis 2013;13 (9):752-61.
Choi WS, Kang CI , Kim Y, Choi JP, Joh JS, Shin HS, et al. Clinical Presentation and Outcomes 
of M iddle East Respiratory  Syndrome in the Republic of Korea. Infect Chemother 
2016;48 (2):118 -26.
de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: Recent Insights Into 
Emerging Coronaviruses. Nature Review 2016;14:523-34.
Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery  S, et al. A Novel Coronavirus 
Associated with Severe Acute Respiratory  Syndrome. N Engl J Med 2003;348 
(20):1953-66.
Lau SK, Chan JF. Coronaviruses: Emerging and Re-Emerging Pathogens in Humans and 
Animals. Virology journal 2015;12:1-3.
VEKLURY, Gilead Sciences Inc. VEKLURY® (remdesivir) for injection, for intravenous use. 
VEKLURY® (remdesivir) injection, for intravenous use. U.S. Prescribing 
Information. Foster City , CA. Revised October.  2020:
Who Mers- Cov Research Group. State of Knowledge and Data Gaps of Middle East Respiratory  
Syndrome Coronavirus (MERS -CoV) in Humans. PL oS currents 2013;5.
Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al. Virological 
Assessment of Hospitalized Patients wi th COVID -2019 [Abstract] [Accepted]. 
Nature 2020.
Zhu N, Zhang D, Wang W, L i X, Yang B, Song J, et al. A Novel Coronavirus from Patients with 
Pneumonia in China, 2019. N Engl J Med 2020.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 66 13January 202111. APPENDICES
Appendix 1. Investigator Signature Page
Appendix 2. Pandemic Ri sk Assessment and Mitigation Plan
Appendix 3. Study Procedures Tables
Appendix 4. Management of Clinical and Laboratory Adverse Events
Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Rerndesivir (RDV; GS-5734 "") 
Protocol GS-US-553-9020 
Gilead Sciences , Inc. 
Appendix 1. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGMENT FINAL 
Amend ment3 
A Phase lb/2a Study in Participants with Early Stage COVID-19 to Evaluate the Safety, 
Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation 
GS-US-553-9020, Amendment 3, 13 January 2021 
This protocol bas been approved by Gilead Sciences, Inc. The following signature documents 
this approval. 
PPD IPPD 
V I 
Date 
INVESTIGATOR STATEMENT 
I have read the protocol , including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personuel under my supervis ion copies of the protocol and access to all 
informa tion provided by Gilead Sciences , Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Princ ipal Investigator Name (Printed) Signature 
Date Site Number 
CONFIDEN TIAL Page 67 l3 January 2021 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 68 13January 2021Appendix 2. Pandemic Risk Assessment and Mitigation Plan
During an ongoing pandemic, potential risks associated with subjects being unable to attend 
study  visits have been identified for this study .
These risks can be summarized as follows:
1)Study  drug supplies to subjects and sites:
a)Subjects may  be unable to return to the site for a number of visits to get the stud y drug, or 
the site may  be unable to accept any  subject visits. Without study
 drugs, the subject 
would not be able to stay on the study  drug as planned per protocol.
Mitigation plan: Study  drug supplies may  be provided to the subject from the site without 
a clinic visit, once it is confirmed that the subject may  safel y continue on study drug as 
determined b y the principal investigator (PI). A virtual study visit, via phone or video 
conferencing, must be performed prior to remote study  drug resuppl y. At the earliest 
opportunity , the site will schedule in -person subject visits and return to the protocol’s 
regular schedule of assessments. A qualified courier may  be utilized to ship the study  
drug from sites to study subjects if permitted b y local ethic scommitt ee/institutional 
review boards ( IRB)/Regulatory  Authority  as applicable and with sponsor’s approval.
b)Shipments of study  drug could be delay ed because of transportation issues. Without study  
drug subject would not be able to stay  on the study  drug as planne d per protocol .
Mitigation plan : The sites’ study  drug inventory  should be closely  monitored. Site staff 
should notify  the sponsor or delegate if they  foresee shortage in study  drug inventory or if 
there is an y interruption in local shipping service. The s ponsor will continue to monitor 
inventory  at the study  drug depot and study  sites. Manual shipments will be triggered as 
necessary .
2)Subject safety monitoring and follow -up:
a)Subjects 
may be unable or unwilling to come to the study  site for their scheduled study  
visits as required per protocol .
Mitigation plan: For subjects who may  be unable or unwilling to visit the study  site for 
their scheduled stud y visits as required per protocol, the PI  or qualified delegate will 
conduct a virtual study visit, via phon e or video conferencing, to assess the subject within 
target visit window date whenever possible. During the virtual stud y visit, the following 
information at minimum will be reviewed:
i)Confirm if subject has experienced an y adverse events (AEs)/serious adv erse events 
(SAEs)/special situations (including pregnancy ) and follow -up on an y unresolved 
AE/SAEs.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 69 13January 2021ii)Review current list of concomitant medications and document any  new concomitant 
medications.
iii)If applicable, confirm electronic diary  questionnaires and pat ient-reported outcomes 
have been completed and transmitted.
iv)If applicable, confirm subjects study  drug suppl y is sufficient to last until the next 
planned visit date. If study  drug resuppl y is needed it will be provided as described 
above in (1).
v)If applic able, remind subject to maintain current dosing and to keep all dispensed 
study  drug kits for return at the next on- site visit.
b)Subjects may  be unable or unwilling to travel to the site for planned assessments 
(eg,safety  blood draws ); hence samples may  not be sent for central lab analy ses.
Mitigation plan: Local labs may  be utilized as appropriate to monitor subject safet y until 
the subject can return to the site for their regular follow -up per protocol. Any  laboratory  
assessments conducted at a local lab due to the pandemic will be documented 
accordingl y.Pregnancy  testing may  be performed using a home urine pregnancy  test if 
local lab pregnancy  testing is not feasible.
c)Subjects may  be unable or unwilling to attend the study  visit to sign an updated informed 
consent form (I CF) version.
Mitigation plan: The site staff will follow their approved consent process and remain in 
compliance with local EC/ IRB and national laws and regulations. Remote consent will be 
allowed if has been approved by  the local EC/IRB.The consent process will be 
documented and confirmed by  normal consent procedure at the earliest opportunity .
3) Protocol and monitoring compliance:
a)Protocol deviations may  occur, in case scheduled visits cannot occur as planned per 
protocol .
Mitigation plan :If it is not possible to complete a required procedure, an unscheduled 
visit should be conducted as soon as possible when conditions allow. The situation should 
be recorded and explained as a protocol deviation. Any  missed subject visits or deviation 
to the protocol due to the pandemic must be reported in the e CRF and described in the 
clinical study  report. Any virtual study  visits that are conducted in lieu of clinic visits due 
to the pandemic will be documented as a protocol deviation related to the pan demic .
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 70 13January 2021b)Monitors may be unable to carry  out source data review or source data verification 
(SDV), or stud y drug accountability  or assess protocol and GCP compliance. This may  
lead to delay s in SDV, an increase in protocol deviations, or under reporting of AE s.
Mitigation plan: The study monitor is to remain in close communication with the site to 
ensure data entry and query  resolution . In compliance with Gilead policy , a remote SDV 
should not be arranged) . The study  monitor is to reference the Study  Monitori ng Plan for 
guidance on how to conduct a remote monitoring visit. The study  staff is to save and 
document all relevant communication in the study  files. 
The status of sites that cannot 
accept monitoring visits and/or subjects on site, must be tracked centrally  and updated on 
a regular basis.
4)Missing data and data integrity :
a)There may  be an i ncreased amount of missing data due to subjects missing 
visits/assessments. This could have an impact on the anal ysis and the interpretation of 
clinical tri al data.
Mitigation plan: Implications of apandemic on methodological aspects for the study  will 
be thoroughly  assessed anddocumented , and relevant actions will be taken as appropriate 
(ie, modification of the statistical anal ysis plan) and in compliance with Regulatory  
Authorities’ guidance. Overall, the clinical study  report will describe the impact of the 
pandemic on the interpretability  of study  data .
Risks will be assessed continuously , and temporary  measures will be implemented to mitigate 
these ris ks as part of a mitigation plan, as described above. These measures will be 
communicated to the relevant stakeholders as appropriate and are intended to provide alternate 
methods that will ensure the evaluation and assessment of the safet y of subjects who are enrolled 
in this study .
Since these potential risks are considered mitigated with the implementation of these measures, 
the expected benefit- risk assessment of RDV in study  subjects remains unchanged.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 71 13January 2021Appendix 3. Study Procedures Table s
Appendix Table 1. Study Parts A and B: Study Procedures Table
Schedule of Assessments ScreeningTREATMENT PERIOD FOLLOW -UP PERIOD
Day 1aDay 2 Day 3 Day 4 Day 5 Day 7Day 14
(±3days)Day 28b 
(±5days)
Obtain Informed Consent X
Inclusion/Exclusion Criteria X
Medical History X
Documentation of SARS -CoV -2 X
ECGcX
Com plete or Symptom -Directed Physical 
ExaminationX X X X X X X X
Body  Weight X
Height X
Vital Signs (Heart Rate, Temperature, Blood 
Pressure, SpO 2)X X X X X X X X
Com pletion of Daily Adapted FLU -PRO©
Questionnaired X X X X X X X
Chest X -RayeX
FEV 1 X X X X X
Safety Laboratory Assessments (Hematology, 
Chemistry, Coagulation)X X X X X
Pregnancy Test (Urine) X
Serum FSH TestfX
Nasopharyngeal and Oropharyngeal Swabs 
and Saliva Samples for 
SARS -CoV- 2 RT -qPCR Testing and Possible 
Viral Resistance TestingX X X X X X X
Sparse Plasma PK AssessmentsgX X
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-553-9020 
Gilead Sciences, Inc. FINAL 
Amendment3 
TREATMENT PERIOD FOLLOW -UP PE RIOD 
Sche dule of A ssessments Screening Day 1• Day 2 Day 3 Day 4 Day s Day 7 Day 14 
(± 3 da ys) Day 28b 
(± 5 da ys) 
---------------------------------------
Inhaled Remdesivir for Injection Formulation X X X X X or PTM Administrationi 
Concomitant Medications X X X X X X X X X 
Adverse Events X X X X X X X X X 
ECG = electrocardiogram; FEY 1 = forced expiratory volume in the first second of expiration; FLU -PRO° = lnFLUenza Patient -Reported Outcome; 
FSH = follicle -stimulating hormone; PCR = polymerase chain reaction; PK= pharmacokinetic(s); RT-qPCR = quantitative reverse transcriptase polymerase 
chain reaction; RDV = (remdesivir, GS 5734-rM); SARS -CoY -2 = severe acute respiratory syndrome coronavirus 2; SpO 2 = oxygen saturation as measured by 
pulse oximetry 
a 
b 
C 
d 
e 
f 
I If the screen ing and Day I visi ts occur on the same day, no procedures need to be repeated. 
Day 28 assessments may be comp leted by telephone . 
ECG will not be re.qu ired at screen ing. However , ECG shou ld be perfom1ed prior to dosing on Day I. If subject random izes and doses on the same day as screen ing, then 
ECG will be done at screen ing. 
Adapted FLU PRO ° quest ionna ire is to be comp leted daily (Days I 14). 
Chest x ray will be perfom1ed at Day I. If screen ing visit and Day I are the same day, chest x ray does not need to be repeated if comp leted as SOC < 2 days before 
screen ing. 
Semm FSH test: Childbeari ng fema le participants who are not postmenopausa l (see Appendix 5 who do not wish to follow protoco l defined contracept ion will need a semm 
FSH test (FSH test is re.qu ired for women who are < 54 years old and have sto ed menstmat ing for 2: 12 months but do not have documentat ion of ovar ian hom10na l failure) 
S arse lasma PK will be collected at Da I end ofnebu lization and Da 3 redose and end ofnebu lization . 
Inha led Remdes 1 vir for Inject ion fomrn lation will be adm inistered to participants at the site under close superv ision. Healthcare profess ionals adm inistering inhaled 
Remdes ivir for Inject ion fomrn lation shou ld have the appropr iate med ication available for immed iate use in case of hypersens itivity. The participant shou ld be treated 
accord ing to the SOC for management of hypersens itivity react ion. After dose adm inistrat ion, mon itoring shou ld be done as follows: Approx imate ly 30 minutes post dose 
adm inistrat ion, participants shou ld be observed , and vital signs shou ld be perfom1ed prior to discharge. 
CON FIDENT IAL Page 72 13 January 2021 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 73 13January 2021Appendix Table 2. Study Part C: Study Procedures Table
Schedule of Assessments ScreeningaTREATMENT PERIOD FOLLOW -UP PERIOD
Day 1bDay 2 Day 3Day 4 Day 5 Day 7Day 14c
(±3days)Day 28c
(±5days)
Obtain Informed Consent X
Inclusion/Exclusion Criteria X
Medical History X
Documentation of SARS -CoV -2dX
Com plete or Symptom -Directed Physical 
ExaminationX X X X X
Body  Weight X
Height X
Vital Signs (Heart Rate, Temperature, Blood 
Pressure, SpO 2)X X X X X
Com pletion of Daily Adapted FLU -PRO©
Questionnairee X X X X X X X
FEV 1 X X X X X
Safety Laboratory Assessments (Hematology, 
Chemistry, Coagulation)X X X X
Pregnancy Test (Urine) X
Serum FSH TestfX
Nasopharyngeal and Oropharyngeal Swabs and 
Saliva Samples for 
SARS -CoV- 2 RT -qPCR Testing and Possible 
Viral Resistance TestingX X X X
Sparse/Single Plasma PK AssessmentsgX X X
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 74 13January 2021Schedule of Assessments ScreeningaTREATMENT PERIOD FOLLOW -UP PERIOD
Day 1bDay 2 Day 3Day 4 Day 5 Day 7Day 14c
(±3days)Day 28c
(±5days)
Remdesivir for Inhalation Solution Formulation or 
PTM Administrationh X X X X X
Concomitant Medications X X X X X X X X X
Adverse Events X X X X X X X X X
COPD  chronic obstructive pulmonary disease; ECG  electrocardiogram; FEV 1forced expiratory volume in the first second of expiration; FLU PRO© InFLUenza 
Patient Reported Outcome; FSH  follicle stimulating hormone; PCR polymerase chain reaction; PK  pharmacokinetic(s); RT qPCR  quantitative reverse transcriptase 
polymerase chain reaction; RDV  (remdesivir, GS 5734™); SARS CoV 2  severe acute respiratory syndrome coronavirus 2; SpO 2 oxygen saturation as measured by pulse 
oximetry
a S tudy visits ,with the exception of the screening visit, may be performed in clinic or at the participant’s home via home health and/or telehealth, virtually or remotely, as 
permitted by local and institutional regulations.
b If the screening and Day 1 visits occur on the same day, no procedures need to be repeated .
c Days 14 and 28 assessments may be completed by telephone.
d Documentation of SARS CoV 2 infection first confirmed by nucleic acid testing or direct antigen testing with sample collected ≤ 4 days prior to randomization  
e Adapted FLU PRO©questionnaire is to be completed daily (Days 1 14).
f Serum FSH test: Childbearing female participants who are not postmenopausal (see Appendix 5) who do not wish to follow protocol defined contraception will need a serum 
FSH test (FSH test is required for women who are < 54 years old and have stopped menstruating for ≥ 12 months but d o not have documentation of ovarian hormonal failure)
g Sparse plasma PK will be collected at Days 3and 5 (predose). A single anytime
PK sample will be collected on Day 7 visit.
h Remdesivir for Inhalation Solution formulation may be administered to participants in the participant’s home with inperson or telehealth support . For participants with 
preexisting pulmonary conditions (ie, COPD or asthma) enrolled in Part C of the study, prescribed inhalers may not be used ≤30 minutes prior to Remdesivir for Inhalation 
Solution formulation administration .Healthcare professionals overseeing Remdesivir for Inhalation Solution formulation therapy remotely will observe the patient for any 
signs of adverse event. If any adverse event is obs erved and cannot be managed remotely, appropriate urgent care measures will be implemented. Approximately 30 minutes 
after dose administration, participants should be observed remotely prior to telehealth support session concluding .
Remde sivir (RDV; GS-5734T") 
Protocol GS-US-553-9020 
Gilead Science s, Inc. FINAL 
Amendment3 
Appendix 4. Manag ement of Clinical and Laborator y Adv erse Events 
Grade 1 Grade 2 
1 : 
e 
on of May continue on th 
study at the discreti 
the invest gato r 
" lfcoofirmed urrelated 
to the study drug. Oosing 
may contirue at the 
discre tion of the 
ilvest igator 
CONFIDENTIAL Grade 3 
+ 
Repeat lab to coofinn 
tocicity grade 
' 
If confirm ed and related 
to study drug, subject 
shou ld be discon tinued 
from thesrudy crug 
Page 75 Grade 4 
- If coofirmed and r elated to 
stud y drug, tl-e 
iwest igational prod.Jct 
should be discoo tinued and 
suqect manag ed acco rding -, to bcal practice. Suq ect 
shou ld be fol owed as 
clilically indi:ated lJlti the 
laboratory abno nnality 
returns to basel ine, or is 
otherw ise exp ailed 
13 Januar y 2021 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 76 13January 2021Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
a.Definition of Childbearing Potential
For the purposes of this study , a female born 
participant is considered of childbearing potential 
until becoming postmenopausal, unless permanently  sterile or with medically  documented 
ovarian failure.
Women are considered to be in a postmenopausal state when they  are > 54 years of age with 
cessation of previously  occurring menses for > 12 months without an alternative cause. In 
addition, women of an y age with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle -stimulating hormone (FSH) level is in the postmenopausal range 
and they  are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpingectomy in a female participant of any  age.
b.Definition of Male Fertility
For the purposes of this study , a male born participant is considered of fertile after the initiation 
of pubert y unless permanently  sterile b y bilateral orchidectom y or with medical documentation.
2)Contraception Requirements for Female Participant s
a.Study Drug Effects on Pregnancy and Hormonal Contraception
In nonclinical reproductive toxicity  studies, RDV demonstrated no adverse effect on embry ofetal 
development when administered to pregnant animals. Embry onic toxicity  was seen when RDV 
was initiated in female animals prior to mati ng and conception, but only  a at a sy stemicall y toxic 
dose. RDV has not yet been studied in pregnant women. Before enrolling participant s into 
studies with RDV, women of childbearing potential must have pregnancy  testing performed at 
screening.
Available d ata indicate that RDV potentially  causes an interaction with hormonal contraception, 
but the effect is considered to be of limited clinical significance. Hormonal methods must be 
used together with a barrier method.
Refer to the latest version of the IB fo r additional information.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 77 13January 2021b.Contraception Requirements for Female Participant s of Childbearing Potential
The inclusion of female participants of childbearing potential requires using at least an 
acceptable effective contraceptive measure. They  must have a negative urine pregnancy  test at 
screening prior to enrollment. I n the event of a delay ed menstrual period (over 1 month between 
menstruations), a pregnancy  test must be performed to rule out pregnancy . This is applicable also 
for women of childbearing potential with infrequent or irregular periods. They  must also agree to 
oneof the following until Day  28:
Complete abstinence from intercourse o f reproductive potential. Abstinence is an acceptable 
method of contraception only  when it is in line with the participant ’s preferred and usual 
lifesty le.
Or
Consistent and correct use of one of the following methods of birth control listed below:
Non-hormonal intrauterine device (IUD)
Hormonal IUD (must be used with a barrier method)
Tubal sterilization
Essure®micro -insert s ystem (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner is the so le sexual partner and 
had confirmation of surgical success 3 months after procedure)
Or
Barrier methods
Female barriers: Diaphragm with spermicide, cervical cap with spermicide, or sponge 
with spermicide
Male barriers: Male condom (with or without spermici de)
Or
Hormonal methods are restricted to drugs associated with the inhibition of ovulation. Each 
method must be used with a barrier method, preferably  male condom. Hormonally -based 
contraceptives permitted for use in this protocol are as follows:
Oral con traceptives (either combined or progesterone only )
Injectable progesterone
Remdesivir (RDV; GS -5734™)
Protocol GS -US-553-9020 FINAL
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 78 13January 2021Subdermal contraceptive implant
Transdermal contraceptive patch
Contraceptive vaginal ring
Female participant s must also refrain from egg donation and in vitro fertilization during 
treatment and until the last investigational product dose.
3) Contraception Requirements for Male Participants
During the study , male participant s with female partners of childbearing potential should use 
condoms until Day 28when engaging in intercourse of reproductive potential.
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (eg, calendar, ovulation, 
symptothermal, postovulation methods), withdrawal (coitus interruptus), spermicides onl y, and 
lactational amenorrhea method. A female condom and a male condom should not be used 
together.
5) Procedures to be Followed in the Event of Pregnancy
Participant s will be instructed to notify the investigator and discontinue investigational product 
immediately ,if they  become pregnant at any  time during the stud y.Participant s whose partner 
has become pregnant or suspects she is pregnant during the stud y must report the information to 
the inve stigator. Instructions for reporting pregnancy , partner pregnancy , and pregnancy outcome 
are outlined in Section 7.4.2.3 .